Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

This increased to 38% and 53% in the 16 and 48‐weeks post‐fracture, respectively. 24% already had a prescription for vitamin D/calcium which increased to 73% at 48‐weeks post‐fracture.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

For this retrospective observational study, we used routinely‐collected general practice (GP) data within the Clinical Practice Research Datalink (CPRD) GOLD together with Office for National Statistics (ONS) mortality data.

Source: Methods.

Patients were included if they received a diagnosis of parkinsonism prior to or during the study period.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism

Observational study · Movement Disorders Clinical Practice · 2026

Original publication title

Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism

Katie C. Naylor; Emily J. Henderson; Emma Tenison

© 2026 The Author(s). Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

There is an osteoporosis treatment gap in Parkinson's rendering an already high‐risk population at further risk of fracture. Men and those with rib fractures are two groups who are least likely to receive potentially beneficial treatment.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.

Source: Objectives

Study methods

What methods does the paper describe?

Data Source

For this retrospective observational study, we used routinely‐collected general practice (GP) data within the Clinical Practice Research Datalink (CPRD) GOLD together with Office for National Statistics (ONS) mortality data. In 2013, CPRD contained 4.4 million active patients, representing 6.9% of the UK population from a network of 674 GP practices, with an additional 6.9 million inactive patients which includes those who have died or are no longer contributing data. 11 Medical events are recorded within the clinical and referral files using Read codes, and prescription medications are recorded using British National Formulary (BNF) coding.

CPRD therefore offers a unique opportunity to study the osteoporosis treatment gap in a large representative cohort of individuals with parkinsonism who have experienced at least one fragility fracture across the UK, where the treatment gap is defined as those who require treatment but are not receiving it within the given population.

Data Extraction

All individuals with a Read code for parkinsonism (excluding drug‐induced parkinsonism, Table A1) in the CPRD clinical and/or referral files who contributed data between January 1, 2010 and December, 31 2019 were extracted. Patients were included if they received a diagnosis of parkinsonism prior to or during the study period. Patients were excluded if: they were censored out of CPRD prior to the study period or the censor date was prior to the first instance of a Read code for parkinsonism, since this suggested a likely data error; they had a Read code for parkinsonism prior to age 35; or there was no available data on primary care prescriptions (CPRD therapy data).

This is because Read codes prior to age 35 potentially relate to a coding error, and the lack of prescription data indicates that there is likely to be further missing data.

Study Population

The index date was the date of the first fragility fracture which occurred in the study period (January 1, 2010: December 31, 2019) for patients with prevalent parkinsonism, registered at a practice contributing data deemed to be of research quality, which is determined by the recording and consistency of variables including practice registration date, transfer out date and date of birth. 12 Patients were followed‐up until they received a prescription for bone protective medication up to a maximum of 48‐weeks; or until they were censored, whichever came first.

This was repeated considering prescriptions for vitamin D and/or calcium supplementation. The censor date was defined as the earliest of: date of death; the last day of data collection at a given GP practice; the date of transfer to another practice without CPRD data‐linkage, or the study end date. If patients received a prescription prior to their fragility fracture, they were not followed up beyond the index date.

In this study, fragility fracture sites considered were hip, vertebrae, wrist/distal radius, humerus, rib, pelvis and unspecified osteoporotic fractures. We followed the methods described by Watson et al 2017 to form a list of Read codes indicating the presence of a fragility fracture (fracture codes) (Table A2). 13 The list was reviewed by two independent clinicians and any discrepancies were agreed by a third clinician. These Read codes were then used to identify patients who experienced at least one fragility fracture during the study period.

Fragility fractures were grouped into fracture events, and the initial fracture event within the study period was retained in the analysis as the index fracture event. Exact duplicates were removed from the dataset. To avoid double counting of fracture events, if two or more fracture codes related to the same fracture site or if an osteoporotic fracture at an unspecified site occurred less than 31 days apart, they were considered to be the same fracture event. Fracture events could consist of more than one specified fracture site if they occurred less than 31 days apart, and information about each fracture present at the event was retained.

Prescription Data

Prescription data relating to either bone protective medications, or vitamin D and/or calcium supplementation were extracted from the CPRD therapy file using the BNF chapters 060602 (bone protective medications), 090604 (vitamin D supplementation), and 09050101 (calcium supplementation). Additionally, the medication descriptions were searched for relevant terms (Table A3), as some drugs were listed in other BNF chapters. Medications were cross‐referenced with the NICE guidelines, and drugs which were not licensed for use in osteoporosis, calcium or vitamin D deficiency, were removed.

Pamidronate was excluded from this list as it is typically used in the context of malignancy. All prescriptions from the CPRD therapy file refer to drugs prescribed/dispensed in primary care for patients in all settings (own home, assisted living, care home etc).

Using index fragility fracture date, we determined whether patients were prescribed bone protective medications or vitamin D and/or calcium supplements before, or whether treatment was initiated after the fracture event. Patients were considered on treatment at the fracture event if prescription for oral bisphosphonates, strontium ranelate or teriparatide were received up to 3 months before; or if denosumab or zoledronate were documented in their medical records up to 9 or 18 months before respectively. These treatment windows were chosen using the standard dosing regimen for denosumab and zoledronate allowing for potential delays in treatment administration.

Based on the UK Fracture Liaison Service gold‐standard, stating that appropriate osteoporosis drug treatment should be commenced within 16‐weeks of a fragility fracture, 14 we analyzed 16‐week time intervals following the fracture event to determine adherence to this standard.

Incomplete Follow‐Up

We considered, within each 16 week time interval, how many patients remained within the study and therefore could have possibly received a prescription. Patients no longer remained within the study if they were censored out (eg, death, transfer out) prior to receiving a prescription. This was considered separately for the bone protective and supplementation prescription data. The patients remaining within each time interval are reported and used as the denominator to calculate the proportion on treatment within each time window.

The total number of patients censored from both the bone protective medications and supplementation data, and the reasons for censorship, are also described.

Bone protective medication and supplementation prescription data were considered separately, since these may not be initiated concurrently, potentially resulting in a patient being censored after prescription of only one medication type.

Statistical Analysis

Stata 18 was used for the analysis. 15 Data are described using mean/standard deviation, and the incidence of fractures is reported per 1000 person‐years with 95% confidence intervals. Logistic regression was used to obtain the prescription probability within a clinically meaningful time window and to test potential predictors of receiving prescriptions including: gender, age (at the mid‐point of the year of birth to the index fragility fracture date), PD duration at the time of fracture (calculated from the date at which the first diagnostic code for parkinsonism was applied), fracture site, Cambridge Multimorbidity Score (CMS) and whether the patient was resident in a care home at the time of fracture.

The CMS quantifies multimorbidity using a count of 37 conditions based on diagnostic and prescription codes. 16 Minimally adjusted models were determined using directed acyclic graphs (Figure A1). Two sensitivity analyses were conducted, restricting the analysis to: (i) patients with an initial diagnosis of PD; (ii) patients with 48‐weeks of data before and after the index fracture to test whether data availability affected any observed relationships.

TABLE A1

Included parkinsonism read codes

Description (as listed in CPRD medical.txt file)MedcodeRead code
Parkinson's disease4321F12.00
Parkinsonism with OH8956F130300
Dementia in Parkinson's disease9509Eu02300
Parkinson's disease NOS14,912F12z.00
Parkinsonism in diseases classified elsewhere86,062Fyu2200
Paralysis agitans1691F120.00
Vascular parkinsonsim100,128F124.00
Lewy body disease7572F116.00
[X]Lewy body dementia26,270Eu02500
Multiple system atrophy22,454F174.00
Shy‐Drager syndrome35,839F130500
Progressive supranuclear palsy9385F24y000
Progressive supranuclear ophthalmoplegia40,553F130400
Steele‐Richardson Oszewski syndrome93,910F24y012
Steele Richardson Oszewski syn49,034F24y011
Steele‐Richardson‐Oszewski syndrome7037F24y200
Supranucelar paralysis29,515F36y000
Corticobasal degeneration107,650F11y200
Cerebral degeneration in Parkinson's disease96,860F11x900
TABLE A2

Included fragility fracture read codes.

Description (as listed in CPRD medical.txt file)MedcodeRead code
Hip
Hip fracture1994S30.11
Fracture of neck of femur2225S30.00
Closed fracture of proximal femur, pertrochanteric5301S302.00
Prmy open red+int fxn prox femoral # + screw/nail+plate device57427K1D000
Closed reduction of fracture of hip66607K1L400
Closed fracture of femur, intertrochanteric8648S302400
Cls red+int fxn proximal femoral # + screw/nail device alone87197K1J000
DHS‐Dynamic hip screw primary fixation of neck of femur97927K1D01E
Hip fracture NOS10,570S30y.11
Dynamic hip screw primary fixation of neck of femur12,5447K1D01F
Cls # prox femur, subcapital, Garden grade unspec.17,019S300500
H/O: hip fracture17,93614G7.00
Closed fracture of neck of femur NOS18,273S30y.00
Cls # proximal femur, trochanteric section, unspecified19,117S302000
Open fracture proximal femur, subcapital, Garden grade III23,803S301800
Closed fracture of unspecified proximal femur24,276S30w.00
Prim open reduct # neck femur & op fix‐Richards screw24,4937K1D01A
Pertrochanteric fracture28,965S304.00
Closed fracture proximal femur, subtrochanteric29,145S302200
Prmy open red+int fxn prox femoral # + screw/nail device alone33,6247K1D600
Closed fracture proximal femur, subcapital, Garden grade II33,957S300700
Closed fracture proximal femur, subcapital, Garden grade IV34,078S300900
Closed fracture proximal femur, subcapital, Garden grade I34,351S300600
Prmy open red+int fxn prox fem # + screw/nail+intramed device34,7647K1D700
Primary int fxn(no red) prox fem # + screw/nail device alone35,0047K1J500
Closed fracture head of femur36,391S300400
Closed fracture proximal femur, subcapital, Garden grade III36,599S300800
Open fracture of neck of femur NOS38,054S30z.00
Closed fracture proximal femur, transcervical38,489S300.00
Primary int fxn(no red) prox fem # + screw/nail+plate device38,8567K1J700
Open fracture proximal femur, subcapital, Garden grade unspec38,878S301500
Open fracture of femur, intertrochanteric39,396S303400
Cls # prox femur, intracapsular section, unspecified39,984S300000
Cl red intracaps fract neck femur fix − Smith‐Petersen nail40,9997K1J012
Primary int fxn(no red) prox fem # + scrw/nail+intramed device44,5947K1J600
Cls # of proximal femur, pertrochanteric section, NOS44,735S302z00
Closed fracture proximal femur, intertrochanteric, two part45,141S302100
Prim open reduct # neck femur & op fix − Neufield nail plate46,2587K1D018
Primary cls red+int fxn prox fem # + screw/nail+plate device46,9597K1JD00
Closed fracture proximal femur, other transcervical49,209S300y00
Opn # proximal femur, intracapsular section, unspecified50,727S301000
Cls # proximal femur, intertrochanteric, comminuted51,216S302300
Closed fracture, base of neck of femur51,861S300311
Open fracture proximal femur, subcapital, Garden grade IV51,999S301900
Closed fracture proximal femur, basicervical52,194S300300
Prim op red # nck femur and op fix‐Charnley compression screw52,3957K1D012
Cl red intracaps frac neck femur fix‐Garden cannulated screw53,6707K1J011
Prim cls rd + int fxn prox fem # + screw/nail+intramdulry device54,8197K1JC00
Primary cls red+int fxn prox fem # + screw/nail device alone55,3867K1JB00
Prim open red # neck femur and op fix‐McLaughlin nail plate56,5687K1D017
Cls red+int fxn prox femoral # + Richard's cannulat hip screw57,5147K1J013
Prim open reduct # neck femur and op fix‐Ross Brown nail57,8847K1D01B
Prim op red # nck femur and op fix‐Zickel intramed nail plate57,8897K1D01D
Open fracture of unspecified proximal femur58,642S30x.00
Prim open reduct # neck femur and op fix‐Blount nail plate58,8177K1D011
Open fracture proximal femur, subcapital, Garden grade I60,885S301600
Open fracture of proximal femur, pertrochanteric61,733S303.00
Closed fracture proximal femur, transcervical, NOS62,966S300z00
Prim open reduct # neck femur and op fix‐Pugh nail plate65,5367K1D019
Closed fracture proximal femur, midcervical section65,690S300200
Open fracture proximal femur, subcapital, Garden grade II67,394S301700
Open # of proximal femur, trochanteric section, unspecified67,633S303000
Closed fracture of femur, subcapital68,229S300y11
Open fracture proximal femur, other transcervical68,668S301y00
Primary external fixation (without reduction) prox femoral #70,0187K1K300
Open fracture of proximal femur, pertrochanteric, NOS70,479S303z00
Open fracture proximal femur, subtrochanteric71,282S303200
Open fracture of femur, subcapital73,234S301y11
Open fracture proximal femur, transcervical73,981S301.00
Closed fracture‐subluxation, hip joint93,374S4E2.00
Prim open reduct # neck femur and op fix‐Holt nail94,7147K1D014
Prim op red # nck femur and op fix‐Deyerle multiple hip pin97,3377K1D013
Open fracture proximal femur, intertrochanteric, comminuted97,971S303300
Open fracture base of neck of femur100,771S301311
Open fracture proximal femur, intertrochanteric, two part101,567S303100
Primary cls reduction+external fixation proximal femoral #102,3137K1K500
Prim open reduct # neck femur and op fix‐Jewett nail plate105,3527K1D015
Prim op red frac neck fem op fix us prox fem nail antirotatn105,8037K1DE00
Remanip intracap fract neck fem and fix using nail or screw107,3587K1Y000
Prim open reduct # neck femur and op fix‐Massie nail plate107,9327K1D016
Open fracture proximal femur, transcervical, NOS112,712S301z00
Open fracture proximal femur, midcervical section112,836S301200
Open fracture proximal femur, basicervical113,426S301300
Closed reduction of intracapsular # NOF internal fixat DHS39,3227K1Jd00
Vertebral fractures
Collapse of vertebra NOS2793N331.12
Closed fracture lumbar vertebra3888S104.00
Collapse of vertebra due to osteoporosis NOS4013N331L00
Fracture of vertebra without spinal cord lesion4409S10.12
Fracture of thoracic vertebra5381S15.00
Collapse of lumbar vertebra due to osteoporosis5841N331J00
Closed fracture lumbar vertebra, wedge8266S104100
Collapse of thoracic vertebra9319N331F00
Fracture of lumbar vertebra10,990S10B000
Collapse of lumbar vertebra11,543N331G00
Other specified closed fracture thoracic vertebra11,770S102y00
Fracture of lumbar spine and pelvis12,406S10B.00
Osteoporosis + pathological fracture thoracic vertebrae12,673N331900
Closed fracture of unspecified cervical vertebra15,613S100000
Collapse of thoracic vertebra15,837N331011
Fatigue fracture of vertebra16,895N1y1.00
Collapse of cervical vertebra17,008N331E00
Osteoporosis + pathological fracture lumbar vertebrae17,377N331800
Collapse of thoracic vertebra due to osteoporosis19,048N331K00
H/O: vertebral fracture19,23514G8.00
Collapse of lumbar vertebra23,686N331111
Closed fracture of seventh cervical vertebra24,672S100700
Closed fracture thoracic vertebra27,404S102.00
Closed fracture of fifth cervical vertebra27,575S100500
Closed fracture of sixth cervical vertebra27,654S100600
Fracture of first cervical vertebra28,133S10A000
Closed fracture thoracic vertebra, wedge28,524S102100
C6 vertebra closed fracture without spinal cord lesion33,503S100611
C2 vertebra closed fracture without spinal cord lesion33,967S100211
Fracture of second cervical vertebra34,403S10A100
C5 vertebra closed fracture without spinal cord lesion34,873S100511
C7 vertebra closed fracture without spinal cord lesion38,053S100711
Collapsed vertebra NOS38,728N331D00
Closed fracture thoracic vertebra not otherwise specified41,138S102z00
Closed fracture of fourth cervical vertebra41,548S100400
C1 vertebra closed fracture: no spinal cord lesion42,561S100111
Osteoporotic vertebral collapse44,386N331.14
Collapse of cervical vertebra due to osteoporosis45,736N331H00
Osteoporosis + pathological fracture cervical vertebrae48,772N331A00
C3 vertebra closed fracture without spinal cord lesion52,699S100311
Closed fracture cervical vertebra, wedge53,337S100H00
Closed fracture of third cervical vertebra60,593S100300
Open fracture lumbar vertebra, wedge65,302S105100
C4 vertebra closed fracture without spinal cord lesion67,358S100411
[X]Collapsed vertebra in diseases classified elsewhere73,900Nyu6700
[X]Fracture of other specified cervical vertebra94,638Syu1500
Collapse of cervical vertebra110,999N331C11
Wrist/distal radius
Wrist fracture: closed203S234.11
Closed reduction of fracture of wrist59517K1LM00
Fracture at wrist and hand level8056S242.00
Wrist fracture: open10,022S235.11
Closed fracture‐subluxation of the wrist17,921S4C2.00
Fracture‐dislocation or subluxation of wrist18,614S4C.00
Closed fracture dislocation of wrist34,429S4C0.00
Open fracture dislocation wrist42,844S4C1.00
[X]Fracture of other and unspecified parts of wrist and hand53,068Syu6500
Open fracture‐subluxation of the wrist59,219S4C3.00
Closed fracture distal radius, extra‐articular, other type19,058S234D00
Closed fracture distal radius, intra‐articular, die‐punch44,844S234C00
Closed fracture distal radius, intra‐articular, other type28,293S234E00
Closed fracture of the distal radius, unspecified1742S234200
Open fracture distal radius, extra‐articular other type53,698S235D00
Open fracture distal radius, intra‐articular other type63,588S235E00
Open fracture distal radius, intra‐articular, die‐punch104,070S235C00
Humerus
Fracture of humerus517S22.00
Fracture of upper end of humerus2101S226.00
Closed reduction of fracture of humerus63797K1LF00
Open fracture of the proximal humerus9420S221.00
Fracture of humerus NOS10,382S22z.00
Closed fracture proximal humerus, greater tuberosity11,044S220300
Closed fracture of the proximal humerus11,222S220.00
Closed fracture proximal humerus, neck11,313S220100
Closed fracture of humerus NOS19,186S222000
Closed fracture of humerus, shaft27,886S222100
Closed fracture proximal humerus, head28,739S220400
Closed fracture proximal humerus, four part29,137S220700
Fracture of shaft of humerus30,659S227.00
Closed fracture of proximal humerus, anatomical neck33,489S220200
Closed fracture of humerus, shaft or unspecified part36,464S222.00
Closed fracture of proximal humerus not otherwise specified38,353S220z00
Closed fracture proximal humerus, three part40,330S220600
Closed fracture of proximal humerus, unspecified part44,721S220000
Open fracture of proximal humerus not otherwise specified45,275S221z00
Open fracture proximal humerus, greater tuberosity48,239S221300
Closed fracture of humerus, upper epiphysis52,406S220500
Open fracture proximal humerus, neck53,622S221100
Open fracture of proximal humerus, unspecified part53,688S221000
Closed fracture of humerus, shaft or unspecified part NOS61,378S222z00
Open fracture proximal humerus, head70,486S221400
Open fracture proximal humerus, three part70,604S221600
Open fracture proximal humerus, four part70,653S221700
Open fracture of proximal humerus, anatomical neck71,207S221200
Rib
Closed fracture rib280S120.00
Closed fracture of rib, unspecified7831S120000
Fracture of rib9688S127.00
Multiple fractures of ribs10,696S127000
Closed fracture multiple ribs11,004S120900
Rib fracture NOS11,378S12z.11
Closed fracture of one rib16,494S120100
Multiple rib fractures17,107S29.12
Closed fracture of rib(s) NOS28,244S120z00
Cough fracture of ribs28,538S127100
Closed fracture of four ribs34,197S120400
Closed fracture of two ribs40,533S120200
Open fracture of two ribs44,826S121200
Open fracture rib48,224S121.00
Closed fracture of five ribs55,424S120500
Closed fracture of three ribs56,384S120300
Closed fracture of six ribs65,484S120600
Closed fracture of eight or more ribs68,652S120800
Open fracture multiple ribs71,452S121900
Open fracture of rib, unspecified73,613S121000
Open fracture of seven ribs73,956S121700
Closed fracture of seven ribs90,494S120700
Open fracture of rib(s) NOS101,560S121z00
Open fracture of one rib112,701S121100
Open fracture of four ribs113,739S121400
Pelvis
Fracture or disruption of pelvis738S13.00
Closed fracture pelvis, multiple pubic rami‐stable6667S132100
Closed fracture pelvis, single pubic ramus7004S132000
Other or multiple closed fracture of pelvis NOS11,639S134z00
Fracture of lumbar spine and pelvis12,406S10B.00
Closed fracture pelvis, coccyx14,834S108.00
Closed fracture of pelvis NOS28,375S13y.00
Other or multiple closed fracture of pelvis33,961S134.00
Closed fracture pelvis, ischium34,708S134100
Closed fracture‐dislocation of pelvis34,910S4J0100
Closed fracture pelvis, multiple pubic rami‐unstable46,592S132200
Unspecified site
Fragility fracture due to unspecified osteoporosis11,503N331M00
H/O: fragility fracture18,73114G6.00
[X]Unspecified osteoporosis with pathological fracture18,825NyuB800
Idiopathic osteoporosis with pathological fracture27,597N331600
Osteoporosis of disuse with pathological fracture33,526N331300
Postmenopausal osteoporosis with pathological fracture38,395N331B00
Postoophorectomy osteoporosis with pathological fracture39,334N331200
Drug‐induced osteoporosis with pathological fracture46,894N331500
[X]Other osteoporosis with pathological fracture57,301NyuB000
Postsurgical malabsorption osteoporosis with path fracture68,019N331400
Fragility fracture93,497N331N00
Minimal trauma fracture due to unspecified osteoporosis93,705N331M11
TABLE A3

Search Terms for prescriptions

Search termTarget
BisphosphonBisphosphonate/Bisphosphonic acid
DisphosphonDiphosphonate/Diphosphonic acid
AlendronAlendronate/Alendronic acid
MK‐217Alendronic acid (Alternative notation)
IbandronIbandronate/Ibandronic acid
RisedronRisedronate/Risedronic acid
ZolendronZoledronate/Zolendronic acid
EtidronEtidronate/Etidronic acid
EHDPEtidronate (alternative notation)
Strontium ranelateStrontium ranelate
Sodium clondronateSodium clondronate
TiludronTilundronate/Tilundronic acid
DenosumabDenosumab
AMG 162Denosumab (alternative notation)
RomosozumabRomosozumab
AMG 785Romosozumab (alternative notation)
TeriparatideTeriparatide
Human parathyroid hormoneHuman parathyroid hormone
AbaloparatideAbaloparatide
BNF chapters
060602Bone protective medications
090604Vitamin D supplementation
09050101Calcium supplementation
Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods

Prescriptions for Bone Protective Medications and Supplementation at Indexed Fracture Event

Results: Prescriptions for Bone Protective Medications and Supplementation at Indexed Fracture Event

Of those with a fragility fracture event, 225 people (12.3%) were on any bone protective medication prior to their fracture. A further 486 people were started on bone protective medication within 48 weeks following their fracture, therefore cumulatively 52.9% were in receipt of a prescription within 48 weeks (Fig. 2A and Table A4). Four hundred and forty two (24.2%) were prescribed vitamin D and/or calcium supplementation prior to their fracture, and a further 651 people were prescribed supplementation up to 48 weeks after their fracture, therefore cumulatively 73.2% were in receipt of a prescription within 48 weeks (Fig. 2B and Table A5).

Figure 2

Stacked bar charts illustrating the prescription of (A) bone protective medication (B) vitamin D/calcium supplementation prior to and following a fragility fracture.

Figure image at the original source: open the original paper. This file is not included in this text import.
TABLE A4

Table of bone protective medication prescriptions over 48 weeks following a fragility fracture

TimelineCensored from study (N)Number of participants a Oral bisphosphonateStrontium ranelateDenosumabZoledronateAll
Before fracture 101823217620225
(Percentage)(11.9%)(0.3%)(0.1%)(0.0%)(12.3%)
Up to 16 weeks after23615875721753597
(Percentage)(36.0%)(1.1%)(0.3%)(0.2%)(37.6%)
Up to 32 weeks after36914546531893683
(Percentage)(44.9%)(1.2%)(0.6%)(0.2%)(47.0%)
Up to 48 weeks after479134467818123711
(Percentage)(50.4%)(1.3%)(0.9%)(0.2%)(52.9%)

Note: This table displays the cumulative frequency of each medication type and all bone protective medications, starting before the fracture event followed by 16 week intervals.

a

The number of people with available data within each time window for bone protective medication.

TABLE A5

Table of vitamin D and/or calcium supplement prescriptions over 48 weeks following a fragility fracture

TimelineCensored from study (N)Number of participants a Supplementation b
Before fracture 101823442
(Percentage)(24.2%)
Up to 16 weeks after1811642951
(Percentage)(57.9%)
Up to 32 weeks after26915541054
(Percentage)(67.8%)
Up to 48 weeks after33014931093
(Percentage)(73.2%)

Note: This table displays the cumulative frequency of supplementation (vitamin D and/or calcium) starting before the fracture event followed by 16 week intervals.

a

The number of people with available data within each time window for supplementation (Vitamin D and/or calcium).

b

Supplementation refers to a prescription being received for vitamin D and/or calcium.

Source: Prescriptions for Bone Protective Medications and Supplementation at Indexed Fracture Event Source: Prescriptions for Bone Protective Medications and Supplementation at Indexed Fracture Event Source: Prescriptions for Bone Protective Medications and Supplementation at Indexed Fracture Event Source: Prescriptions for Bone Protective Medications and Supplementation at Indexed Fracture Event

Results: Incomplete Follow‐Up

A total of 479 patients were censored from the bone protective medication data within 48 weeks of a fragility fracture, due to 123 deaths, 53 patients reaching the last point of data collection from the practice, 207 transferring to a GP practice without CPRD linkage, and 96 reaching the end of the study period prior to a prescription being issued (Figure A2). Of the 1598, who were not prescribed bone protective medication prior to their fragility fracture, the mean follow‐up time was 1.2 years (SD = 1.6 years, range 0 days to 9.7 years).

With respect to vitamin D and/or calcium prescriptions, a total of 330 patients were censored within 48 weeks of a fragility fracture, due to 92 deaths, 37 patients reaching the last point of data collection from the practice, 149 transferring to a GP practice without CPRD linkage, and 52 reaching the end of the study period prior to a prescription being issued (Figure A3). Of the 1381, who were not prescribed vitamin D and/or calcium prior to their fragility fracture, the mean follow‐up time was 0.9 years (SD = 1.5 years, range 0 days to 9.7 years).

Source: Incomplete Follow‐Up Source: Incomplete Follow‐Up

Results: Predictors of Bone Protective Prescriptions

We explored demographic factors and fracture site as predictors of bone protective prescriptions being issued (Table 2). Being female (OR 2.06 [95% CI (1.69 to 2.51)], p < 0.001) and being aged 75 to 79 (OR 1.82 [95% CI (1.40 to 2.37)], p < 0.001), 80 to 84 (OR 1.67 [95% CI (1.28 to 2.17)], p < 0.001) or over 85 (OR 1.63 [95% CI (1.24 to 2.16)], p = 0.001), increased the odds of bone protective medication prescription. Residing in a care home reduced the odds of bone protective medication prescription (OR 0.64 [95% CI (0.43 to 0.96)], p = 0.03).

Sustaining a vertebral fracture (OR 1.84 [95% CI (1.38 to 2.45)], p < 0.001), or having unspecified fragility fracture recorded (OR 1.76 [95% CI (1.33 to 2.33)], p < 0.001), when compared to sustaining a hip fracture, also increased the odds of bone protective medication prescription, whereas sustaining a rib fracture (OR 0.28 [95% CI (0.16 to 0.49)], p < 0.001) reduced the odds.

TABLE 2

Unadjusted logistic regression models to look at factors predicting bone protective medication prescriptions

Unadjusted odds ratio (95% CI)N p‐value
Gender
Maleref1823
Female2.06 (1.69 to 2.51)<0.001
Age
35 to 74ref1823
74 to 791.82 (1.40 to 2.37)<0.001
80 to 841.67 (1.28 to 2.17)<0.001
85+1.63 (1.24 to 2.16)0.001
PD duration
Less than 1 yearref1823
1 to 2.4 years0.78 (0.59 to 1.03)0.08
2.5 to 4 years0.80 (0.61 to 1.05)0.11
5 to 9 years0.79 (0.59 to 1.05)0.10
10+ years0.76 (0.54 to 1.07)0.12
Fracture type
Hipref1823
Vertebral1.84 (1.38 to 2.45)<0.001
Wrist0.68 (0.44 to 1.05)0.08
Humerus0.80 (0.57 to 1.12)0.19
Rib0.28 (0.16 to 0.49)<0.001
Pelvis1.14 (0.71 to 1.85)0.58
Unspecified1.76 (1.33 to 2.33)<0.001
Multiple Fractures1.30 (0.62 to 2.71)0.49
Cambridge multimorbidity score
0/1ref1823
20.82 (0.51 to 1.33)0.42
30.83 (0.53 to 1.31)0.43
40.91 (0.58 to 1.43)0.68
50.93 (0.59 to 1.46)0.74
60.95 (0.59 to 1.52)0.83
7+0.88 (0.56 to 1.38)0.57
Care home residence
Not living in care homeref1823
Living in care home0.64 (0.43 to 0.96)0.03

When adjusting for age and gender, vertebral fractures (OR 2.06 [95% CI (1.53 to 2.77)], p < 0.001) had stronger association with receiving a prescription whereas unspecified fracture (OR 1.57 [95% CI (1.17 to 2.10)], p < 0.001), and rib fractures (OR 0.34 [95% CI (0.19 to 0.60)], p < 0.001) both had a slightly attenuated relationship with receiving a prescription for bone protective medication versus hip fracture. When adjusting for age, multi‐morbidity (CMS) and gender, living in a care home (OR 0.58 [95% CI (0.38 to 0.88)], p = 0.01) had a stronger association of decreasing the odds of receiving a prescription than in the univariate model.

Multimorbidity still did not change the odds of receiving a prescription after adjusting for age (Table 3). The direction of these associations was not altered when restricting the analysis to those with an initial diagnosis of PD or those with 48 weeks of data before and after the index fracture, although it did weaken the association between prescriptions and care home residency (Table A6 and A7).

TABLE 3

Minimally adjusted logistic regression models to look at factors predicting bone protective medication prescriptions

Odds ratio (95% CI)N p‐value
Fracture type (unadjusted)
Hipref1823
Vertebral1.84 (1.38 to 2.45)<0.001
Wrist0.68 (0.44 to 1.05)0.08
Humerus0.80 (0.57 to 1.12)0.19
Rib0.28 (0.16 to 0.49)<0.001
Pelvis1.14 (0.71 to 1.85)0.58
Unspecified1.76 (1.33 to 2.33)<0.001
Multiple Fractures1.30 (0.62 to 2.71)0.49
Fracture type adjusted for age
Hipref1823
Vertebral1.98 (1.48 to 2.65)<0.001
Wrist0.75 (0.49 to 1.17)0.21
Humerus0.82 (0.58 to 1.16)0.26
Rib0.31 (0.18 to 0.55)<0.001
Pelvis1.15 (0.71 to 1.86)0.57
Unspecified1.84 (1.39 to 2.44)<0.001
Multiple fractures1.29 (0.62 to 2.71)0.50
Fracture type adjusted for age and gender
Hipref1823
Vertebral2.06 (1.53 to 2.77)<0.001
Wrist0.60 (0.38 to 0.93)0.02
Humerus0.72 (0.50 to 1.02)0.06
Rib0.34 (0.19 to 0.60)<0.001
Pelvis0.99 (0.61 to 1.61)0.96
Unspecified1.57 (1.17 to 2.10)<0.001
Multiple fractures1.23 (0.58 to 2.61)0.59
Cambridge multimorbidity score (unadjusted)
0/1ref1823
20.82 (0.51 to 1.33)0.42
30.83 (0.53 to 1.31)0.43
40.91 (0.58 to 1.43)0.68
50.93 (0.59 to 1.46)0.74
60.95 (0.59 to 1.52)0.83
7+0.88 (0.56 to 1.38)0.57
Cambridge multimorbidity score adjusted for age
0/1ref1823
20.77 (0.47 to 1.25)0.29
30.76 (0.48 to 1.21)0.25
40.81 (0.51 to 1.28)0.37
50.81 (0.51 to 1.28)0.36
60.82 (0.51 to 1.32)0.41
7+0.77 (0.49 to 1.21)0.26
Care home residency (unadjusted)
Noref1823
Yes0.64 (0.43 to 0.96)0.03
Care home residency adjusted for age
Noref1823
Yes0.58 (0.39 to 0.88)0.01
Care home residency adjusted for age and gender
Noref1823
Yes0.58 (0.38 to 0.88)0.01
Care home residency adjusted for age, gender and CMS
Noref1823
Yes0.58 (0.38 to 0.88)0.01
TABLE A6

Sensitivity analysis restricted to those with an initial diagnosis of Parkinson's disease

Odds ratio (95% CI)N p‐value
Fracture type (unadjusted)
Hipref1521
Vertebral1.79 (1.31 to 2.43)< 0.001
Wrist0.64 (0.40 to 1.02)0.06
Humerus0.72 (0.50 to 1.04)0.08
Rib0.25 (0.13 to 0.46)< 0.001
Pelvis1.00 (0.57 to 1.73)0.99
Unspecified1.69 (1.24 to 2.30)< 0.001
Multiple fractures1.38 (0.61 to 3.12)0.44
Fracture type adjusted for age
Hipref1521
Vertebral1.91 (1.40 to 2.61)< 0.001
Wrist0.72 (0.45 to 1.16)0.18
Humerus0.74 (0.51 to 1.08)0.12
Rib0.28 (0.15 to 0.53)< 0.001
Pelvis1.00 (0.57 to 1.75)1.00
Unspecified1.79 (1.31 to 2.44)< 0.001
Multiple fractures1.40 (0.61 to 3.19)0.42
Fracture type adjusted for age and gender
Hipref1521
Vertebral2.04 (1.48 to 2.81)< 0.001
Wrist0.56 (0.34 to 0.91)0.02
Humerus0.64 (0.44 to 0.94)0.02
Rib0.31 (0.16 to 0.58)< 0.001
Pelvis0.85 (0.48 to 1.49)0.56
Unspecified1.53 (1.11 to 2.10)0.01
Multiple Fractures1.31 (0.56 to 3.02)0.53
Cambridge multimorbidity score unadjusted
0/1ref1521
20.80 (0.48 to 1.36)0.42
30.80 (0.48 to 1.33)0.39
40.88 (0.53 to 1.45)0.61
50.95 (0.58 to 1.57)0.85
60.97 (0.58 to 1.63)0.92
7+0.87 (0.53 to 1.43)0.58
Cambridge multimorbidity score adjusted for age
0/1ref1521
20.74 (0.44 to 1.27)0.28
30.74 (0.44 to 1.23)0.24
40.79 (0.48 to 1.31)0.36
50.84 (0.50 to 1.40)0.49
60.83 (0.49 to 1.41)0.50
7+0.76 (0.46 to 1.26)0.29
Care home residence (Unadjusted) a
Not living in care homeref1521
Living in care home0.75 (0.48 to 1.17)0.20
Care home residence adjusted for age
Not living in care homeref1521
Living in care home0.68 (0.44 to 1.07)0.10
Care home residence adjusted for age and gender
Not living in care homeref1521
Living in care home0.69 (0.44 to 1.08)0.11
Care home residence adjusted for age, gender and CMS
Not living in care homeref1521
Living in care home0.68 (0.43 to 1.08)0.10
a

There are now 94 (6.2%) of patients living in a care home.

TABLE A7

Sensitivity analysis restricted to those with 48‐weeks of data before and after the index fracture

Odds ratio (95% CI)N p‐value
Fracture type (Unadjusted)
Hipref765
Vertebral1.64 (1.05 to 2.56)0.03
Wrist0.58 (0.32 to 1.05)0.07
Humerus0.67 (0.39 to 1.13)0.13
Rib0.22 (0.10 to 0.48)<0.001
Pelvis0.56 (0.25 to 1.27)0.17
Unspecified1.57 (1.05 to 2.36)0.03
Multiple Fractures1.31 (0.37 to 4.63)0.67
Fracture type adjusted for age
Hipref765
Vertebral1.73 (1.10 to 2.71)0.02
Wrist0.62 (0.34 to 1.14)0.13
Humerus0.69 (0.40 to 1.17)0.17
Rib0.24 (0.11 to 0.52)<0.001
Pelvis0.57 (0.25 to 1.30)0.18
Unspecified1.61 (1.07 to 2.42)0.02
Multiple Fractures1.36 (0.38 to 4.84)0.64
Fracture type adjusted for age and gender
Hipref765
Vertebral1.78 (1.12 to 2.82)0.01
Wrist0.50 (0.27 to 0.94)0.03
Humerus0.60 (0.35 to 1.03)0.06
Rib0.26 (0.12 to 0.57)< 0.001
Pelvis0.48 (0.21 to 1.10)0.08
Unspecified1.44 (0.95 to 2.19)0.09
Multiple Fractures1.30 (0.36 to 4.69)0.69
Cambridge multimorbidity score unadjusted
0/1ref765
20.66 (0.29 to 1.48)0.31
30.85 (0.40 to 1.81)0.67
41.02 (0.48 to 2.16)0.96
50.85 (0.39 to 1.84)0.68
61.16 (0.53 to 2.56)0.71
7+1.08 (0.51 to 2.29)0.84
Cambridge multimorbidity score adjusted for age
0/1ref765
20.60 (0.26 to 1.37)0.23
30.79 (0.36 to 1.70)0.54
40.90 (0.42 to 1.93)0.78
50.76 (0.34 to 1.66)0.48
60.97 (0.43 to 2.17)0.93
7+0.91 (0.42 to 1.95)0.80
Care home residence (unadjusted) a
Not living in care homeref765
Living in care home0.54 (0.24 to 1.18)0.12
Care home residence adjusted for age
Not living in care homeref765
Living in care home0.48 (0.22 to 1.07)0.07
Care home residence adjusted for age and gender
Not living in care homeref765
Living in care home0.47 (0.21 to 1.05)0.07
Care home residence adjusted for age, gender and CMS
Not living in care homeref765
Living in care home0.44 (0.20 to 1.00)0.05
a

There are now 31 (4.1%) of patients living in a care home.

Source: Predictors of Bone Protective Prescriptions Source: Predictors of Bone Protective Prescriptions Source: Predictors of Bone Protective Prescriptions Source: Predictors of Bone Protective Prescriptions Source: Predictors of Bone Protective Prescriptions Source: Predictors of Bone Protective Prescriptions

Discussion

Despite a significantly increased risk of sustaining fragility fractures, bone‐health and osteoporosis management is often overlooked when caring for people with parkinsonism. To understand the extent to which osteoporosis is treated in line with national guidelines, we investigated whether either bone protective medications, vitamin D and/or calcium supplements were prescribed. This was based on primary care records before and after people experienced fragility fractures. We identified treatment gaps and investigated potential predictors of prescriptions being made within 48 weeks following a fracture.

We identified a fracture rate of 27.3 per 1000 person years which aligns with the current literature. 6 , 17 Consistent with our previous findings 18 and with the results of the Parkinson's UK National Audit, 9 we identified a substantial treatment gap. Only 38% of this real‐world population who sustained a fragility fracture were receiving treatment within the recommended 16 week period. Increasing the treatment window to 48 weeks post fracture only increased this proportion to 53%. More people were prescribed vitamin D and/or calcium supplementation within 16 (58%) and 48 weeks (73%).

Being female, aged >75 years and having sustained either a vertebral or unspecified fragility fracture increased the odds of receiving a prescription for bone protective medications. Conversely, people with parkinsonism who had sustained rib fracture(s), or were residing in a care home were less likely to be prescribed bone protective medication. The direction of these associations was maintained when restricting the analysis to those with: more complete data (Table A7); or an initial diagnosis of PD (Table A6).

Due to initial diagnostic uncertainty, it is possible that some PD diagnoses may subsequently have been revised to an atypical parkinsonism. 19

Whilst demonstrating this striking and stark treatment gap, we have considered additional factors which may have impacted this finding. Using CPRD data it is possible to see which patients were prescribed bone protective medication in primary care. There is insufficient data to reliably determine whether bone health was considered and then no treatment was initiated (appropriately), adherence to prescribed treatments, or whether patients had received intravenous zoledronate via secondary care. There are several reasons why osteoporosis treatment may have been deemed inappropriate despite a patient sustaining a fragility fracture, including: concerns over polypharmacy; upper gastrointestinal disorders; renal impairment; patient preferences; bisphosphonate treatment holidays; life‐expectancy; concerns over side‐effects; or fracture risk assessment concluding treatment wasn’t warranted. 20 , 21 These legitimate reasons why treatments are sometimes not initiated will contribute to an over‐estimation of the reported treatment gap.

We might hypothesize that individuals with greater co‐morbidity burden are less likely to receive a prescription, but this was not evident in our data.

It is unclear to what extent the inability to capture treatment with zoledronate affects the treatment gap during the study period (2010 to 2019). Data from the National Hip Fracture Database (NHFD) indicates that in 2020 only 9% of patients were started on zoledronate following a hip fracture, 22 , 23 and in 2021 NOGG guidance was updated to recommend zoledronate as a first‐line treatment. 21 , 24 Prior to 2021, the recommendation was to use zoledronate if first‐line treatments, alendronate and risedronate, were not tolerated or contraindicated. 25 , 26 However, given that people with PD commonly experience difficulty swallowing, 27 perhaps oral bisphosphonates were deemed inappropriate and zoledronate was considered a suitable alternative in some instances.

Therefore, the inability to capture zoledronate may contribute to an over‐estimation of the identified treatment gap, however this gap is unlikely to be fully explained by this.

We excluded missing data from the treatment gap analysis. However, it is also important to consider those who did not receive a prescription before the last collection date for the practice, the end of the study period or who transferred to a practice without CPRD follow‐up. It is possible that these patients were later provided osteoporosis treatment. Amongst patients who died within 48 weeks and did not receive bone protective medication or supplementation, this may indicate a clinical decision that treatment was unlikely to be beneficial due to limited life expectancy.

When exploring demographic factors as predictors for bone protective medication prescription, it was unsurprising that being female compared to male increased the odds of prescriptions (OR 2.06 [95% CI (1.69 to 2.51)], p<0.001), given the known gender disparities in the treatment of osteoporosis. Recent work has demonstrated that in vertebral fracture cohorts the odds ratio for treatment was 1.82 favoring women 28 and, at hospital discharge following a hip fracture, only 2.7% (n = 3/110) of men compared to 27% (n = 60/253) of women were on anti‐resorptive treatment in a single center study in the United States. 29

Fracture type also affected the odds of receiving a prescription for bone protective medications. Vertebral fractures (OR 2.06 [1.53 to 2.77], p < 0.001) and unspecified osteoporotic fractures (OR 1.57 [1.17 to 2.10], p < 0.001) when compared to hip fracture increased the odds, whereas rib fractures (OR 0.34 [0.19 to 0.60], p < 0.001) when compared to hip fractures decreased the odds of prescription. We hypothesize that this could be explained by the different inpatient treatment received, although this cannot be addressed using CPRD data.

In the UK, rib fractures, unlike hip fractures, are more variably managed in different inpatient locations besides geriatrics, including orthopedics and general surgery 30 where there may be less familiarity with the use of osteoporosis treatments potentially leading to a discrepancy in the recommendation for bone protective medications. The finding that those with vertebral versus hip fracture have increased odds of receiving a prescription reflects findings from the US that following a vertebral fracture there is the largest increase in osteoporosis diagnosis and treatment rates compared to other fracture types. 31

Care home residency also reduced the odds of prescription after adjustment for age, gender and number of comorbidities (OR 0.58 [0.38 to 0.88], p = 0.01). However, the evidence for this was weakened when restricting the analysis to those with an initial diagnosis of PD or to those with 48 weeks of data before and after the index fracture. This is most likely explained by the small number of patients who were resident in a care home in these sub‐groups (Table A6 and A7) therefore widening the confidence interval.

This result is consistent with findings from US care home residents with dementia and high fracture risk, where only 11.6% received fracture prevention medications. 32 The authors also highlighted a potential lack of awareness about the appropriateness of treatment, as 10% of those receiving hospice care and 11% of individuals who were not dependent for activities of daily living were receiving medication for fracture prevention reflecting over and under‐treatment respectively. 32 Whilst the appropriateness of treatment could not be assessed in our study, it is important to consider that treatment for osteoporosis should be considered on a case‐by‐case basis accounting for several patient factors regardless of whether the patient resides in a care home.

TABLE A7

Sensitivity analysis restricted to those with 48‐weeks of data before and after the index fracture

Odds ratio (95% CI)N p‐value
Fracture type (Unadjusted)
Hipref765
Vertebral1.64 (1.05 to 2.56)0.03
Wrist0.58 (0.32 to 1.05)0.07
Humerus0.67 (0.39 to 1.13)0.13
Rib0.22 (0.10 to 0.48)<0.001
Pelvis0.56 (0.25 to 1.27)0.17
Unspecified1.57 (1.05 to 2.36)0.03
Multiple Fractures1.31 (0.37 to 4.63)0.67
Fracture type adjusted for age
Hipref765
Vertebral1.73 (1.10 to 2.71)0.02
Wrist0.62 (0.34 to 1.14)0.13
Humerus0.69 (0.40 to 1.17)0.17
Rib0.24 (0.11 to 0.52)<0.001
Pelvis0.57 (0.25 to 1.30)0.18
Unspecified1.61 (1.07 to 2.42)0.02
Multiple Fractures1.36 (0.38 to 4.84)0.64
Fracture type adjusted for age and gender
Hipref765
Vertebral1.78 (1.12 to 2.82)0.01
Wrist0.50 (0.27 to 0.94)0.03
Humerus0.60 (0.35 to 1.03)0.06
Rib0.26 (0.12 to 0.57)< 0.001
Pelvis0.48 (0.21 to 1.10)0.08
Unspecified1.44 (0.95 to 2.19)0.09
Multiple Fractures1.30 (0.36 to 4.69)0.69
Cambridge multimorbidity score unadjusted
0/1ref765
20.66 (0.29 to 1.48)0.31
30.85 (0.40 to 1.81)0.67
41.02 (0.48 to 2.16)0.96
50.85 (0.39 to 1.84)0.68
61.16 (0.53 to 2.56)0.71
7+1.08 (0.51 to 2.29)0.84
Cambridge multimorbidity score adjusted for age
0/1ref765
20.60 (0.26 to 1.37)0.23
30.79 (0.36 to 1.70)0.54
40.90 (0.42 to 1.93)0.78
50.76 (0.34 to 1.66)0.48
60.97 (0.43 to 2.17)0.93
7+0.91 (0.42 to 1.95)0.80
Care home residence (unadjusted) a
Not living in care homeref765
Living in care home0.54 (0.24 to 1.18)0.12
Care home residence adjusted for age
Not living in care homeref765
Living in care home0.48 (0.22 to 1.07)0.07
Care home residence adjusted for age and gender
Not living in care homeref765
Living in care home0.47 (0.21 to 1.05)0.07
Care home residence adjusted for age, gender and CMS
Not living in care homeref765
Living in care home0.44 (0.20 to 1.00)0.05
a

There are now 31 (4.1%) of patients living in a care home.

TABLE A6

Sensitivity analysis restricted to those with an initial diagnosis of Parkinson's disease

Odds ratio (95% CI)N p‐value
Fracture type (unadjusted)
Hipref1521
Vertebral1.79 (1.31 to 2.43)< 0.001
Wrist0.64 (0.40 to 1.02)0.06
Humerus0.72 (0.50 to 1.04)0.08
Rib0.25 (0.13 to 0.46)< 0.001
Pelvis1.00 (0.57 to 1.73)0.99
Unspecified1.69 (1.24 to 2.30)< 0.001
Multiple fractures1.38 (0.61 to 3.12)0.44
Fracture type adjusted for age
Hipref1521
Vertebral1.91 (1.40 to 2.61)< 0.001
Wrist0.72 (0.45 to 1.16)0.18
Humerus0.74 (0.51 to 1.08)0.12
Rib0.28 (0.15 to 0.53)< 0.001
Pelvis1.00 (0.57 to 1.75)1.00
Unspecified1.79 (1.31 to 2.44)< 0.001
Multiple fractures1.40 (0.61 to 3.19)0.42
Fracture type adjusted for age and gender
Hipref1521
Vertebral2.04 (1.48 to 2.81)< 0.001
Wrist0.56 (0.34 to 0.91)0.02
Humerus0.64 (0.44 to 0.94)0.02
Rib0.31 (0.16 to 0.58)< 0.001
Pelvis0.85 (0.48 to 1.49)0.56
Unspecified1.53 (1.11 to 2.10)0.01
Multiple Fractures1.31 (0.56 to 3.02)0.53
Cambridge multimorbidity score unadjusted
0/1ref1521
20.80 (0.48 to 1.36)0.42
30.80 (0.48 to 1.33)0.39
40.88 (0.53 to 1.45)0.61
50.95 (0.58 to 1.57)0.85
60.97 (0.58 to 1.63)0.92
7+0.87 (0.53 to 1.43)0.58
Cambridge multimorbidity score adjusted for age
0/1ref1521
20.74 (0.44 to 1.27)0.28
30.74 (0.44 to 1.23)0.24
40.79 (0.48 to 1.31)0.36
50.84 (0.50 to 1.40)0.49
60.83 (0.49 to 1.41)0.50
7+0.76 (0.46 to 1.26)0.29
Care home residence (Unadjusted) a
Not living in care homeref1521
Living in care home0.75 (0.48 to 1.17)0.20
Care home residence adjusted for age
Not living in care homeref1521
Living in care home0.68 (0.44 to 1.07)0.10
Care home residence adjusted for age and gender
Not living in care homeref1521
Living in care home0.69 (0.44 to 1.08)0.11
Care home residence adjusted for age, gender and CMS
Not living in care homeref1521
Living in care home0.68 (0.43 to 1.08)0.10
a

There are now 94 (6.2%) of patients living in a care home.

Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion

What strengths and limitations does the paper describe?

This study is strengthened by the ability to assess the management of osteoporosis in a large, representative cohort of people with Parkinsonism across the United Kingdom. By using CPRD data it is possible to include previously under‐represented groups such as those who are older, with more advanced parkinsonism, care home residents, as well as people across the spectrum of parkinsonian disorders. 33 This is of particular importance given that people with atypical parkinsonism have greater fracture risk, alongside an osteoporosis treatment gap, 34 , 35 and there is often diagnostic uncertainty. 19

It was beyond the scope of this paper to ascertain whether patients were adherent to prescribed treatment or whether health care professional follow‐up was provided to maximize adherence. 14 Adherence to osteoporosis treatment is a well‐documented issue; persistence to oral bisphosphonates amongst post‐menopausal women is reported to be only 28% at 12 months. 36 Therefore, despite prescriptions being made it is likely that many patients were still without treatment following a fragility fracture.

When determining if patients were on treatment prior to fracture, for oral bisphosphonates patients were considered “on‐treatment” if they received a prescription in the 3 months prior to their fracture. However, this could mis‐classify participants if they were on treatment holiday after previously being prescribed oral bisphosphonates. It was also likely that patients being given zoledronate are mis‐categorized as “untreated” as it is not administered in the primary care setting and is therefore not reliably recorded within the CPRD data.

Furthermore, patients could have been misclassified as “not taking supplementation” if they are using over‐the‐counter vitamin D and/or calcium. However over‐the‐counter formulations may be sub‐standard in comparison to licensed medical products. 37 All of which could contribute to the observed treatment gaps.

As previously discussed, it is also possible that treatment options were considered and deemed inappropriate or declined by patients; however, this information is not routinely coded in CPRD data. It is also not possible using CPRD data to determine the circumstances surrounding the fracture. Whilst we included fracture sites typically associated with fragility fractures, it is possible that some of these fractures occurred from a trauma greater than a fall from standing height and are also contributing to an over‐estimation of the treatment gap as they are not indicative of osteoporosis.

Additionally, this population includes all people with parkinsonism who experienced a fracture between 2010 and 2019; in this study we consider the treatment decisions made after only the initial fracture which occurred within this period. However, it is possible that patients had multiple fracture events within this period or had fractures prior to 1st January 2010. Furthermore, the data available to us for analysis pre‐dates the updated NOGG guidance which mentions Parkinson's as an osteoporosis risk factor, 21 and our guidance on managing bone‐health in parkinsonism. 18 , 38 However, the treatment gap identified remains consistent with our 2025 findings that less than one third of people with parkinsonism are treated in‐line with the NOGG guidelines. 18

There remains a significant osteoporosis treatment gap within the parkinsonian population. Men with parkinsonism, those living in a care home, and those who sustain rib fractures are at increased odds of not receiving a prescription for bone protective medication following a fracture. Addressing this gap might reasonably be expected to prevent future fragility fractures and the associated serious and negative sequalae in this vulnerable and at‐risk population.

Source: Strengths and Limitations Source: Strengths and Limitations Source: Strengths and Limitations Source: Strengths and Limitations Source: Strengths and Limitations Source: Strengths and Limitations

Author Roles

(1) Research project: A. Conception, B. Organization, C. Execution, (2) Statistical analysis: A. Design, B. Execution, C. Review and critique; (3) Manuscript preparation: A. Writing of the first draft, B. Review and critique.

K.C.N.: 1A, 1B, 1C, 2A, 2B, 3A.

E.J.H.: 1A, 1B, 1C, 2A, 2C, 3B.

E.T.: 1A, 1B, 1C, 2A, 2C, 3B.

Source: Author Roles Source: Author Roles Source: Author Roles Source: Author Roles

Results

We identified 21,792 people with parkinsonism, of whom 211 were excluded (n = 1 and n = 136 due to censoring before the study period or first parkinsonism code respectively; n = 33 due to missing prescription data; n = 41 due to age Fig. 1). The mean duration of available data was 3.1 years (SD = 2.5 years, range 1 day to 10.0 years). The mean age of patients at entry to the cohort was 74.7 years (SD = 9.9).

Figure 1

Flowchart showing the inclusion/exclusion of people from study population.

Figure image at the original source: open the original paper. This file is not included in this text import.

There were 1823 (8.4%) people with parkinsonism who had at least one fragility fracture during the study period. The incidence rate of fragility fractures was 27.3 per 1000 person‐years (95% CI = 26.1 to 28.6). The mean age at the time of fracture was 78.9 (SD = 7.79) years. Of those who experienced a fracture within the study period, hip fractures were the most common, experienced by 813 people (44.6%), followed by vertebral fractures in 255 people (14.0%). Within a 31‐day period, which we assumed to relate to the same fracture event, only 29 (1.6%) people experienced two different fractures and 1 (0.1%) experienced three (Table 1).

TABLE 1

Demographic characteristics of the parkinsonian cohort identified in clinical practice research datalink (CPRD) 2010 to 2019, and the fracture subgroup

Full cohortFracture subgroup
Mean (SD) or N (%)Mean (SD) or N (%)
N21,5811823
Age upon entry to cohort a 74.7 (9.8)76.5 (8.1)
Sex
Male12,942 (60.0%)751 (41.2%)
Female8639 (40.0%)1072 (58.8%)
PD duration (years)1.4 (3.5)1.9 (3.7)
Diagnosis
Parkinson's disease17,897 (82.9%)1521 (83.4%)
Dementia with Lewy bodies1716 (8.0%)122 (6.7%)
Vascular Parkinsonism929 (4.3%)78 (4.3%)
Progressive supranuclear palsy374 (1.7%)37 (2.0%)
Parkinson's disease dementia206 (1.0%)15 (0.8%)
Multiple system atrophy166 (0.8%)10 (0.5%)
Corticobasal degeneration65 (0.3%)4 (0.2%)
Parkinsonism12 (0.1%)0
Other b 216 (1.0%)36 (2.0%)
Years of available CPRD data3.1 (2.5)4.3 (2.6)
Fragility fracture present in study period
None19,758 (91.6%)Not reported
One or more1823 (8.4%)Not reported
How many individual fractures occurred in this first event?
1 FractureNot reported1793 (98.4%)
2 FracturesNot reported29 (1.6%)
3 FracturesNot reported1 (0.1%)
Age at fractureNot reported78.9 (7.8)
Fracture site c
HipNot reported813 (44.6%)
VertebralNot reported255 (14.0%)
WristNot reported125 (6.9%)
HumerusNot reported197 (10.8%)
RibNot reported115 (6.3%)
PelvisNot reported78 (4.3%)
UnspecifiedNot reported269 (14.8%)
a

This is age on January 1, 2010 for those diagnosed with Parkinson's before the study period began, or age on the day of Parkinson's diagnosis if diagnosed during the study period.

b

This includes the Read codes for paralysis agitans, Parkinson's orthostatic hypotension and cerebral degeneration PD, all of which indicate Parkinsonism.

c

These frequencies reflect the number of participants whom experienced a fracture at each site rather than the number of fractures.

Prescriptions for Bone Protective Medications and Supplementation at Indexed Fracture Event

Of those with a fragility fracture event, 225 people (12.3%) were on any bone protective medication prior to their fracture. A further 486 people were started on bone protective medication within 48 weeks following their fracture, therefore cumulatively 52.9% were in receipt of a prescription within 48 weeks (Fig. 2A and Table A4). Four hundred and forty two (24.2%) were prescribed vitamin D and/or calcium supplementation prior to their fracture, and a further 651 people were prescribed supplementation up to 48 weeks after their fracture, therefore cumulatively 73.2% were in receipt of a prescription within 48 weeks (Fig. 2B and Table A5).

Figure 2

Stacked bar charts illustrating the prescription of (A) bone protective medication (B) vitamin D/calcium supplementation prior to and following a fragility fracture.

Figure image at the original source: open the original paper. This file is not included in this text import.

Incomplete Follow‐Up

A total of 479 patients were censored from the bone protective medication data within 48 weeks of a fragility fracture, due to 123 deaths, 53 patients reaching the last point of data collection from the practice, 207 transferring to a GP practice without CPRD linkage, and 96 reaching the end of the study period prior to a prescription being issued (Figure A2). Of the 1598, who were not prescribed bone protective medication prior to their fragility fracture, the mean follow‐up time was 1.2 years (SD = 1.6 years, range 0 days to 9.7 years).

With respect to vitamin D and/or calcium prescriptions, a total of 330 patients were censored within 48 weeks of a fragility fracture, due to 92 deaths, 37 patients reaching the last point of data collection from the practice, 149 transferring to a GP practice without CPRD linkage, and 52 reaching the end of the study period prior to a prescription being issued (Figure A3). Of the 1381, who were not prescribed vitamin D and/or calcium prior to their fragility fracture, the mean follow‐up time was 0.9 years (SD = 1.5 years, range 0 days to 9.7 years).

Predictors of Bone Protective Prescriptions

We explored demographic factors and fracture site as predictors of bone protective prescriptions being issued (Table 2). Being female (OR 2.06 [95% CI (1.69 to 2.51)], p < 0.001) and being aged 75 to 79 (OR 1.82 [95% CI (1.40 to 2.37)], p < 0.001), 80 to 84 (OR 1.67 [95% CI (1.28 to 2.17)], p < 0.001) or over 85 (OR 1.63 [95% CI (1.24 to 2.16)], p = 0.001), increased the odds of bone protective medication prescription. Residing in a care home reduced the odds of bone protective medication prescription (OR 0.64 [95% CI (0.43 to 0.96)], p = 0.03).

Sustaining a vertebral fracture (OR 1.84 [95% CI (1.38 to 2.45)], p < 0.001), or having unspecified fragility fracture recorded (OR 1.76 [95% CI (1.33 to 2.33)], p < 0.001), when compared to sustaining a hip fracture, also increased the odds of bone protective medication prescription, whereas sustaining a rib fracture (OR 0.28 [95% CI (0.16 to 0.49)], p < 0.001) reduced the odds.

TABLE 2

Unadjusted logistic regression models to look at factors predicting bone protective medication prescriptions

Unadjusted odds ratio (95% CI)N p‐value
Gender
Maleref1823
Female2.06 (1.69 to 2.51)<0.001
Age
35 to 74ref1823
74 to 791.82 (1.40 to 2.37)<0.001
80 to 841.67 (1.28 to 2.17)<0.001
85+1.63 (1.24 to 2.16)0.001
PD duration
Less than 1 yearref1823
1 to 2.4 years0.78 (0.59 to 1.03)0.08
2.5 to 4 years0.80 (0.61 to 1.05)0.11
5 to 9 years0.79 (0.59 to 1.05)0.10
10+ years0.76 (0.54 to 1.07)0.12
Fracture type
Hipref1823
Vertebral1.84 (1.38 to 2.45)<0.001
Wrist0.68 (0.44 to 1.05)0.08
Humerus0.80 (0.57 to 1.12)0.19
Rib0.28 (0.16 to 0.49)<0.001
Pelvis1.14 (0.71 to 1.85)0.58
Unspecified1.76 (1.33 to 2.33)<0.001
Multiple Fractures1.30 (0.62 to 2.71)0.49
Cambridge multimorbidity score
0/1ref1823
20.82 (0.51 to 1.33)0.42
30.83 (0.53 to 1.31)0.43
40.91 (0.58 to 1.43)0.68
50.93 (0.59 to 1.46)0.74
60.95 (0.59 to 1.52)0.83
7+0.88 (0.56 to 1.38)0.57
Care home residence
Not living in care homeref1823
Living in care home0.64 (0.43 to 0.96)0.03

When adjusting for age and gender, vertebral fractures (OR 2.06 [95% CI (1.53 to 2.77)], p < 0.001) had stronger association with receiving a prescription whereas unspecified fracture (OR 1.57 [95% CI (1.17 to 2.10)], p < 0.001), and rib fractures (OR 0.34 [95% CI (0.19 to 0.60)], p < 0.001) both had a slightly attenuated relationship with receiving a prescription for bone protective medication versus hip fracture. When adjusting for age, multi‐morbidity (CMS) and gender, living in a care home (OR 0.58 [95% CI (0.38 to 0.88)], p = 0.01) had a stronger association of decreasing the odds of receiving a prescription than in the univariate model.

Multimorbidity still did not change the odds of receiving a prescription after adjusting for age (Table 3). The direction of these associations was not altered when restricting the analysis to those with an initial diagnosis of PD or those with 48 weeks of data before and after the index fracture, although it did weaken the association between prescriptions and care home residency (Table A6 and A7).

TABLE 3

Minimally adjusted logistic regression models to look at factors predicting bone protective medication prescriptions

Odds ratio (95% CI)N p‐value
Fracture type (unadjusted)
Hipref1823
Vertebral1.84 (1.38 to 2.45)<0.001
Wrist0.68 (0.44 to 1.05)0.08
Humerus0.80 (0.57 to 1.12)0.19
Rib0.28 (0.16 to 0.49)<0.001
Pelvis1.14 (0.71 to 1.85)0.58
Unspecified1.76 (1.33 to 2.33)<0.001
Multiple Fractures1.30 (0.62 to 2.71)0.49
Fracture type adjusted for age
Hipref1823
Vertebral1.98 (1.48 to 2.65)<0.001
Wrist0.75 (0.49 to 1.17)0.21
Humerus0.82 (0.58 to 1.16)0.26
Rib0.31 (0.18 to 0.55)<0.001
Pelvis1.15 (0.71 to 1.86)0.57
Unspecified1.84 (1.39 to 2.44)<0.001
Multiple fractures1.29 (0.62 to 2.71)0.50
Fracture type adjusted for age and gender
Hipref1823
Vertebral2.06 (1.53 to 2.77)<0.001
Wrist0.60 (0.38 to 0.93)0.02
Humerus0.72 (0.50 to 1.02)0.06
Rib0.34 (0.19 to 0.60)<0.001
Pelvis0.99 (0.61 to 1.61)0.96
Unspecified1.57 (1.17 to 2.10)<0.001
Multiple fractures1.23 (0.58 to 2.61)0.59
Cambridge multimorbidity score (unadjusted)
0/1ref1823
20.82 (0.51 to 1.33)0.42
30.83 (0.53 to 1.31)0.43
40.91 (0.58 to 1.43)0.68
50.93 (0.59 to 1.46)0.74
60.95 (0.59 to 1.52)0.83
7+0.88 (0.56 to 1.38)0.57
Cambridge multimorbidity score adjusted for age
0/1ref1823
20.77 (0.47 to 1.25)0.29
30.76 (0.48 to 1.21)0.25
40.81 (0.51 to 1.28)0.37
50.81 (0.51 to 1.28)0.36
60.82 (0.51 to 1.32)0.41
7+0.77 (0.49 to 1.21)0.26
Care home residency (unadjusted)
Noref1823
Yes0.64 (0.43 to 0.96)0.03
Care home residency adjusted for age
Noref1823
Yes0.58 (0.39 to 0.88)0.01
Care home residency adjusted for age and gender
Noref1823
Yes0.58 (0.38 to 0.88)0.01
Care home residency adjusted for age, gender and CMS
Noref1823
Yes0.58 (0.38 to 0.88)0.01
TABLE A4

Table of bone protective medication prescriptions over 48 weeks following a fragility fracture

TimelineCensored from study (N)Number of participants a Oral bisphosphonateStrontium ranelateDenosumabZoledronateAll
Before fracture 101823217620225
(Percentage)(11.9%)(0.3%)(0.1%)(0.0%)(12.3%)
Up to 16 weeks after23615875721753597
(Percentage)(36.0%)(1.1%)(0.3%)(0.2%)(37.6%)
Up to 32 weeks after36914546531893683
(Percentage)(44.9%)(1.2%)(0.6%)(0.2%)(47.0%)
Up to 48 weeks after479134467818123711
(Percentage)(50.4%)(1.3%)(0.9%)(0.2%)(52.9%)

Note: This table displays the cumulative frequency of each medication type and all bone protective medications, starting before the fracture event followed by 16 week intervals.

a

The number of people with available data within each time window for bone protective medication.

TABLE A5

Table of vitamin D and/or calcium supplement prescriptions over 48 weeks following a fragility fracture

TimelineCensored from study (N)Number of participants a Supplementation b
Before fracture 101823442
(Percentage)(24.2%)
Up to 16 weeks after1811642951
(Percentage)(57.9%)
Up to 32 weeks after26915541054
(Percentage)(67.8%)
Up to 48 weeks after33014931093
(Percentage)(73.2%)

Note: This table displays the cumulative frequency of supplementation (vitamin D and/or calcium) starting before the fracture event followed by 16 week intervals.

a

The number of people with available data within each time window for supplementation (Vitamin D and/or calcium).

b

Supplementation refers to a prescription being received for vitamin D and/or calcium.

TABLE A6

Sensitivity analysis restricted to those with an initial diagnosis of Parkinson's disease

Odds ratio (95% CI)N p‐value
Fracture type (unadjusted)
Hipref1521
Vertebral1.79 (1.31 to 2.43)< 0.001
Wrist0.64 (0.40 to 1.02)0.06
Humerus0.72 (0.50 to 1.04)0.08
Rib0.25 (0.13 to 0.46)< 0.001
Pelvis1.00 (0.57 to 1.73)0.99
Unspecified1.69 (1.24 to 2.30)< 0.001
Multiple fractures1.38 (0.61 to 3.12)0.44
Fracture type adjusted for age
Hipref1521
Vertebral1.91 (1.40 to 2.61)< 0.001
Wrist0.72 (0.45 to 1.16)0.18
Humerus0.74 (0.51 to 1.08)0.12
Rib0.28 (0.15 to 0.53)< 0.001
Pelvis1.00 (0.57 to 1.75)1.00
Unspecified1.79 (1.31 to 2.44)< 0.001
Multiple fractures1.40 (0.61 to 3.19)0.42
Fracture type adjusted for age and gender
Hipref1521
Vertebral2.04 (1.48 to 2.81)< 0.001
Wrist0.56 (0.34 to 0.91)0.02
Humerus0.64 (0.44 to 0.94)0.02
Rib0.31 (0.16 to 0.58)< 0.001
Pelvis0.85 (0.48 to 1.49)0.56
Unspecified1.53 (1.11 to 2.10)0.01
Multiple Fractures1.31 (0.56 to 3.02)0.53
Cambridge multimorbidity score unadjusted
0/1ref1521
20.80 (0.48 to 1.36)0.42
30.80 (0.48 to 1.33)0.39
40.88 (0.53 to 1.45)0.61
50.95 (0.58 to 1.57)0.85
60.97 (0.58 to 1.63)0.92
7+0.87 (0.53 to 1.43)0.58
Cambridge multimorbidity score adjusted for age
0/1ref1521
20.74 (0.44 to 1.27)0.28
30.74 (0.44 to 1.23)0.24
40.79 (0.48 to 1.31)0.36
50.84 (0.50 to 1.40)0.49
60.83 (0.49 to 1.41)0.50
7+0.76 (0.46 to 1.26)0.29
Care home residence (Unadjusted) a
Not living in care homeref1521
Living in care home0.75 (0.48 to 1.17)0.20
Care home residence adjusted for age
Not living in care homeref1521
Living in care home0.68 (0.44 to 1.07)0.10
Care home residence adjusted for age and gender
Not living in care homeref1521
Living in care home0.69 (0.44 to 1.08)0.11
Care home residence adjusted for age, gender and CMS
Not living in care homeref1521
Living in care home0.68 (0.43 to 1.08)0.10
a

There are now 94 (6.2%) of patients living in a care home.

TABLE A7

Sensitivity analysis restricted to those with 48‐weeks of data before and after the index fracture

Odds ratio (95% CI)N p‐value
Fracture type (Unadjusted)
Hipref765
Vertebral1.64 (1.05 to 2.56)0.03
Wrist0.58 (0.32 to 1.05)0.07
Humerus0.67 (0.39 to 1.13)0.13
Rib0.22 (0.10 to 0.48)<0.001
Pelvis0.56 (0.25 to 1.27)0.17
Unspecified1.57 (1.05 to 2.36)0.03
Multiple Fractures1.31 (0.37 to 4.63)0.67
Fracture type adjusted for age
Hipref765
Vertebral1.73 (1.10 to 2.71)0.02
Wrist0.62 (0.34 to 1.14)0.13
Humerus0.69 (0.40 to 1.17)0.17
Rib0.24 (0.11 to 0.52)<0.001
Pelvis0.57 (0.25 to 1.30)0.18
Unspecified1.61 (1.07 to 2.42)0.02
Multiple Fractures1.36 (0.38 to 4.84)0.64
Fracture type adjusted for age and gender
Hipref765
Vertebral1.78 (1.12 to 2.82)0.01
Wrist0.50 (0.27 to 0.94)0.03
Humerus0.60 (0.35 to 1.03)0.06
Rib0.26 (0.12 to 0.57)< 0.001
Pelvis0.48 (0.21 to 1.10)0.08
Unspecified1.44 (0.95 to 2.19)0.09
Multiple Fractures1.30 (0.36 to 4.69)0.69
Cambridge multimorbidity score unadjusted
0/1ref765
20.66 (0.29 to 1.48)0.31
30.85 (0.40 to 1.81)0.67
41.02 (0.48 to 2.16)0.96
50.85 (0.39 to 1.84)0.68
61.16 (0.53 to 2.56)0.71
7+1.08 (0.51 to 2.29)0.84
Cambridge multimorbidity score adjusted for age
0/1ref765
20.60 (0.26 to 1.37)0.23
30.79 (0.36 to 1.70)0.54
40.90 (0.42 to 1.93)0.78
50.76 (0.34 to 1.66)0.48
60.97 (0.43 to 2.17)0.93
7+0.91 (0.42 to 1.95)0.80
Care home residence (unadjusted) a
Not living in care homeref765
Living in care home0.54 (0.24 to 1.18)0.12
Care home residence adjusted for age
Not living in care homeref765
Living in care home0.48 (0.22 to 1.07)0.07
Care home residence adjusted for age and gender
Not living in care homeref765
Living in care home0.47 (0.21 to 1.05)0.07
Care home residence adjusted for age, gender and CMS
Not living in care homeref765
Living in care home0.44 (0.20 to 1.00)0.05
a

There are now 31 (4.1%) of patients living in a care home.

Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results

Abstract: Conclusions

There is an osteoporosis treatment gap in Parkinson's rendering an already high‐risk population at further risk of fracture. Men and those with rib fractures are two groups who are least likely to receive potentially beneficial treatment.

Source: Conclusions
Authors’ abstract

Abstract

Background

Fracture risk is increased in Parkinson's yet this risk is often not addressed.

Objectives

Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.

Methods

The clinical practice research datalink (CPRD) GOLD data contains anonymized UK primary care data. We identified fragility fractures (hip, vertebrae, wrist/distal radius, humerus, rib, pelvis and unspecified osteoporotic) amongst prevalent parkinsonism patients between 2010 and 2019, and ascertained whether bone protective medications and/or vitamin D/calcium supplements were prescribed in the pre‐fracture period or in the 48‐weeks post‐fracture. Logistic regression was used to determine predictors of prescriptions.

Results

There were 21,581 people with parkinsonism (mean age 74.7 ± 9.8 years, 40% female), with a mean of 3.1 ± 2.5 years of available data. One thousand eight hundred twenty‐three experienced at least one fragility fracture. Prior to a fragility fracture 12% had a prescription for bone protective medication. This increased to 38% and 53% in the 16 and 48‐weeks post‐fracture, respectively. 24% already had a prescription for vitamin D/calcium which increased to 73% at 48‐weeks post‐fracture. Female gender (OR = 2.06 [1.69 to 2.51], p < 0.001) and sustaining a vertebral fracture (OR = 2.06 [1.53 to 2.77], p < 0.001) increased the odds of bone protection prescriptions.

However, sustaining a rib fracture (OR = 0.34 [0.19 to 0.60], p < 0.001) or residing in a care home (OR = 0.58 [0.38 to 0.88], p = 0.01) decreased the odds.

Conclusions

There is an osteoporosis treatment gap in Parkinson's rendering an already high‐risk population at further risk of fracture. Men and those with rib fractures are two groups who are least likely to receive potentially beneficial treatment.

Read the full paper

In Parkinson's disease (PD), lower bone mineral density (BMD) and increased incidence of falls lead to an increased fragility fracture risk. 1 , 2 Compared to age and gender‐matched controls, people with PD are at 2‐fold increased risk of osteoporotic fracture, and 3‐fold increased risk for hip fracture. 3 Furthermore, people with PD are more likely to develop complications 4 , 5 or have difficulty regaining mobility 6 following hip fracture and mortality is over twice that of age‐matched controls. 7

In Parkinson's care bone health and osteoporosis prevention and treatment are often overlooked. In their 2020 UK‐wide national audit, Parkinson's UK reported that, of 1131 patients, 73% did not have an up‐to‐date fracture risk assessment 8 ; and that only 18.5% of respondents recalled osteoporosis or fracture risk being discussed with specialists. 9 The lack of attention to fracture risk is further compounded by the fact that people with PD under‐estimate their fracture risk. 10

In the UK, according to the gold‐standard fracture liaison services (FLS), following a fragility fracture patients are expected to have a bone health assessment to determine if they are: low risk, and therefore offered life‐style advice to minimize their risk of future fractures; or high risk, and are therefore offered osteoporosis drug treatment.

Since bone health is often overlooked, we assessed the extent to which these treatment guidelines were followed in a population with parkinsonism following a fragility fracture. We sought to: (1) understand the extent to which bone protective medications and calcium/vitamin D were prescribed within 16 and 48‐weeks of a fragility fracture; (2) identify demographic and clinical factors which predict prescriptions being made using logistic regression.

Methods

Data Source

For this retrospective observational study, we used routinely‐collected general practice (GP) data within the Clinical Practice Research Datalink (CPRD) GOLD together with Office for National Statistics (ONS) mortality data. In 2013, CPRD contained 4.4 million active patients, representing 6.9% of the UK population from a network of 674 GP practices, with an additional 6.9 million inactive patients which includes those who have died or are no longer contributing data. 11 Medical events are recorded within the clinical and referral files using Read codes, and prescription medications are recorded using British National Formulary (BNF) coding.

CPRD therefore offers a unique opportunity to study the osteoporosis treatment gap in a large representative cohort of individuals with parkinsonism who have experienced at least one fragility fracture across the UK, where the treatment gap is defined as those who require treatment but are not receiving it within the given population.

Data Extraction

All individuals with a Read code for parkinsonism (excluding drug‐induced parkinsonism, Table A1) in the CPRD clinical and/or referral files who contributed data between January 1, 2010 and December, 31 2019 were extracted. Patients were included if they received a diagnosis of parkinsonism prior to or during the study period. Patients were excluded if: they were censored out of CPRD prior to the study period or the censor date was prior to the first instance of a Read code for parkinsonism, since this suggested a likely data error; they had a Read code for parkinsonism prior to age 35; or there was no available data on primary care prescriptions (CPRD therapy data).

This is because Read codes prior to age 35 potentially relate to a coding error, and the lack of prescription data indicates that there is likely to be further missing data.

Study Population

The index date was the date of the first fragility fracture which occurred in the study period (January 1, 2010: December 31, 2019) for patients with prevalent parkinsonism, registered at a practice contributing data deemed to be of research quality, which is determined by the recording and consistency of variables including practice registration date, transfer out date and date of birth. 12 Patients were followed‐up until they received a prescription for bone protective medication up to a maximum of 48‐weeks; or until they were censored, whichever came first.

This was repeated considering prescriptions for vitamin D and/or calcium supplementation. The censor date was defined as the earliest of: date of death; the last day of data collection at a given GP practice; the date of transfer to another practice without CPRD data‐linkage, or the study end date. If patients received a prescription prior to their fragility fracture, they were not followed up beyond the index date.

In this study, fragility fracture sites considered were hip, vertebrae, wrist/distal radius, humerus, rib, pelvis and unspecified osteoporotic fractures. We followed the methods described by Watson et al 2017 to form a list of Read codes indicating the presence of a fragility fracture (fracture codes) (Table A2). 13 The list was reviewed by two independent clinicians and any discrepancies were agreed by a third clinician. These Read codes were then used to identify patients who experienced at least one fragility fracture during the study period.

Fragility fractures were grouped into fracture events, and the initial fracture event within the study period was retained in the analysis as the index fracture event. Exact duplicates were removed from the dataset. To avoid double counting of fracture events, if two or more fracture codes related to the same fracture site or if an osteoporotic fracture at an unspecified site occurred less than 31 days apart, they were considered to be the same fracture event. Fracture events could consist of more than one specified fracture site if they occurred less than 31 days apart, and information about each fracture present at the event was retained.

Prescription Data

Prescription data relating to either bone protective medications, or vitamin D and/or calcium supplementation were extracted from the CPRD therapy file using the BNF chapters 060602 (bone protective medications), 090604 (vitamin D supplementation), and 09050101 (calcium supplementation). Additionally, the medication descriptions were searched for relevant terms (Table A3), as some drugs were listed in other BNF chapters. Medications were cross‐referenced with the NICE guidelines, and drugs which were not licensed for use in osteoporosis, calcium or vitamin D deficiency, were removed.

Pamidronate was excluded from this list as it is typically used in the context of malignancy. All prescriptions from the CPRD therapy file refer to drugs prescribed/dispensed in primary care for patients in all settings (own home, assisted living, care home etc).

Using index fragility fracture date, we determined whether patients were prescribed bone protective medications or vitamin D and/or calcium supplements before, or whether treatment was initiated after the fracture event. Patients were considered on treatment at the fracture event if prescription for oral bisphosphonates, strontium ranelate or teriparatide were received up to 3 months before; or if denosumab or zoledronate were documented in their medical records up to 9 or 18 months before respectively. These treatment windows were chosen using the standard dosing regimen for denosumab and zoledronate allowing for potential delays in treatment administration.

Based on the UK Fracture Liaison Service gold‐standard, stating that appropriate osteoporosis drug treatment should be commenced within 16‐weeks of a fragility fracture, 14 we analyzed 16‐week time intervals following the fracture event to determine adherence to this standard.

Incomplete Follow‐Up

We considered, within each 16 week time interval, how many patients remained within the study and therefore could have possibly received a prescription. Patients no longer remained within the study if they were censored out (eg, death, transfer out) prior to receiving a prescription. This was considered separately for the bone protective and supplementation prescription data. The patients remaining within each time interval are reported and used as the denominator to calculate the proportion on treatment within each time window.

The total number of patients censored from both the bone protective medications and supplementation data, and the reasons for censorship, are also described.

Bone protective medication and supplementation prescription data were considered separately, since these may not be initiated concurrently, potentially resulting in a patient being censored after prescription of only one medication type.

Statistical Analysis

Stata 18 was used for the analysis. 15 Data are described using mean/standard deviation, and the incidence of fractures is reported per 1000 person‐years with 95% confidence intervals. Logistic regression was used to obtain the prescription probability within a clinically meaningful time window and to test potential predictors of receiving prescriptions including: gender, age (at the mid‐point of the year of birth to the index fragility fracture date), PD duration at the time of fracture (calculated from the date at which the first diagnostic code for parkinsonism was applied), fracture site, Cambridge Multimorbidity Score (CMS) and whether the patient was resident in a care home at the time of fracture.

The CMS quantifies multimorbidity using a count of 37 conditions based on diagnostic and prescription codes. 16 Minimally adjusted models were determined using directed acyclic graphs (Figure A1). Two sensitivity analyses were conducted, restricting the analysis to: (i) patients with an initial diagnosis of PD; (ii) patients with 48‐weeks of data before and after the index fracture to test whether data availability affected any observed relationships.

Results

We identified 21,792 people with parkinsonism, of whom 211 were excluded (n = 1 and n = 136 due to censoring before the study period or first parkinsonism code respectively; n = 33 due to missing prescription data; n = 41 due to age Fig. 1). The mean duration of available data was 3.1 years (SD = 2.5 years, range 1 day to 10.0 years). The mean age of patients at entry to the cohort was 74.7 years (SD = 9.9).

Figure 1

Flowchart showing the inclusion/exclusion of people from study population.

Figure image at the original source: open the original paper. This file is not included in this text import.

There were 1823 (8.4%) people with parkinsonism who had at least one fragility fracture during the study period. The incidence rate of fragility fractures was 27.3 per 1000 person‐years (95% CI = 26.1 to 28.6). The mean age at the time of fracture was 78.9 (SD = 7.79) years. Of those who experienced a fracture within the study period, hip fractures were the most common, experienced by 813 people (44.6%), followed by vertebral fractures in 255 people (14.0%). Within a 31‐day period, which we assumed to relate to the same fracture event, only 29 (1.6%) people experienced two different fractures and 1 (0.1%) experienced three (Table 1).

TABLE 1

Demographic characteristics of the parkinsonian cohort identified in clinical practice research datalink (CPRD) 2010 to 2019, and the fracture subgroup

Full cohortFracture subgroup
Mean (SD) or N (%)Mean (SD) or N (%)
N21,5811823
Age upon entry to cohort a 74.7 (9.8)76.5 (8.1)
Sex
Male12,942 (60.0%)751 (41.2%)
Female8639 (40.0%)1072 (58.8%)
PD duration (years)1.4 (3.5)1.9 (3.7)
Diagnosis
Parkinson's disease17,897 (82.9%)1521 (83.4%)
Dementia with Lewy bodies1716 (8.0%)122 (6.7%)
Vascular Parkinsonism929 (4.3%)78 (4.3%)
Progressive supranuclear palsy374 (1.7%)37 (2.0%)
Parkinson's disease dementia206 (1.0%)15 (0.8%)
Multiple system atrophy166 (0.8%)10 (0.5%)
Corticobasal degeneration65 (0.3%)4 (0.2%)
Parkinsonism12 (0.1%)0
Other b 216 (1.0%)36 (2.0%)
Years of available CPRD data3.1 (2.5)4.3 (2.6)
Fragility fracture present in study period
None19,758 (91.6%)Not reported
One or more1823 (8.4%)Not reported
How many individual fractures occurred in this first event?
1 FractureNot reported1793 (98.4%)
2 FracturesNot reported29 (1.6%)
3 FracturesNot reported1 (0.1%)
Age at fractureNot reported78.9 (7.8)
Fracture site c
HipNot reported813 (44.6%)
VertebralNot reported255 (14.0%)
WristNot reported125 (6.9%)
HumerusNot reported197 (10.8%)
RibNot reported115 (6.3%)
PelvisNot reported78 (4.3%)
UnspecifiedNot reported269 (14.8%)
a

This is age on January 1, 2010 for those diagnosed with Parkinson's before the study period began, or age on the day of Parkinson's diagnosis if diagnosed during the study period.

b

This includes the Read codes for paralysis agitans, Parkinson's orthostatic hypotension and cerebral degeneration PD, all of which indicate Parkinsonism.

c

These frequencies reflect the number of participants whom experienced a fracture at each site rather than the number of fractures.

Prescriptions for Bone Protective Medications and Supplementation at Indexed Fracture Event

Of those with a fragility fracture event, 225 people (12.3%) were on any bone protective medication prior to their fracture. A further 486 people were started on bone protective medication within 48 weeks following their fracture, therefore cumulatively 52.9% were in receipt of a prescription within 48 weeks (Fig. 2A and Table A4). Four hundred and forty two (24.2%) were prescribed vitamin D and/or calcium supplementation prior to their fracture, and a further 651 people were prescribed supplementation up to 48 weeks after their fracture, therefore cumulatively 73.2% were in receipt of a prescription within 48 weeks (Fig. 2B and Table A5).

Figure 2

Stacked bar charts illustrating the prescription of (A) bone protective medication (B) vitamin D/calcium supplementation prior to and following a fragility fracture.

Figure image at the original source: open the original paper. This file is not included in this text import.

Incomplete Follow‐Up

A total of 479 patients were censored from the bone protective medication data within 48 weeks of a fragility fracture, due to 123 deaths, 53 patients reaching the last point of data collection from the practice, 207 transferring to a GP practice without CPRD linkage, and 96 reaching the end of the study period prior to a prescription being issued (Figure A2). Of the 1598, who were not prescribed bone protective medication prior to their fragility fracture, the mean follow‐up time was 1.2 years (SD = 1.6 years, range 0 days to 9.7 years).

With respect to vitamin D and/or calcium prescriptions, a total of 330 patients were censored within 48 weeks of a fragility fracture, due to 92 deaths, 37 patients reaching the last point of data collection from the practice, 149 transferring to a GP practice without CPRD linkage, and 52 reaching the end of the study period prior to a prescription being issued (Figure A3). Of the 1381, who were not prescribed vitamin D and/or calcium prior to their fragility fracture, the mean follow‐up time was 0.9 years (SD = 1.5 years, range 0 days to 9.7 years).

Predictors of Bone Protective Prescriptions

We explored demographic factors and fracture site as predictors of bone protective prescriptions being issued (Table 2). Being female (OR 2.06 [95% CI (1.69 to 2.51)], p < 0.001) and being aged 75 to 79 (OR 1.82 [95% CI (1.40 to 2.37)], p < 0.001), 80 to 84 (OR 1.67 [95% CI (1.28 to 2.17)], p < 0.001) or over 85 (OR 1.63 [95% CI (1.24 to 2.16)], p = 0.001), increased the odds of bone protective medication prescription. Residing in a care home reduced the odds of bone protective medication prescription (OR 0.64 [95% CI (0.43 to 0.96)], p = 0.03).

Sustaining a vertebral fracture (OR 1.84 [95% CI (1.38 to 2.45)], p < 0.001), or having unspecified fragility fracture recorded (OR 1.76 [95% CI (1.33 to 2.33)], p < 0.001), when compared to sustaining a hip fracture, also increased the odds of bone protective medication prescription, whereas sustaining a rib fracture (OR 0.28 [95% CI (0.16 to 0.49)], p < 0.001) reduced the odds.

TABLE 2

Unadjusted logistic regression models to look at factors predicting bone protective medication prescriptions

Unadjusted odds ratio (95% CI)N p‐value
Gender
Maleref1823
Female2.06 (1.69 to 2.51)<0.001
Age
35 to 74ref1823
74 to 791.82 (1.40 to 2.37)<0.001
80 to 841.67 (1.28 to 2.17)<0.001
85+1.63 (1.24 to 2.16)0.001
PD duration
Less than 1 yearref1823
1 to 2.4 years0.78 (0.59 to 1.03)0.08
2.5 to 4 years0.80 (0.61 to 1.05)0.11
5 to 9 years0.79 (0.59 to 1.05)0.10
10+ years0.76 (0.54 to 1.07)0.12
Fracture type
Hipref1823
Vertebral1.84 (1.38 to 2.45)<0.001
Wrist0.68 (0.44 to 1.05)0.08
Humerus0.80 (0.57 to 1.12)0.19
Rib0.28 (0.16 to 0.49)<0.001
Pelvis1.14 (0.71 to 1.85)0.58
Unspecified1.76 (1.33 to 2.33)<0.001
Multiple Fractures1.30 (0.62 to 2.71)0.49
Cambridge multimorbidity score
0/1ref1823
20.82 (0.51 to 1.33)0.42
30.83 (0.53 to 1.31)0.43
40.91 (0.58 to 1.43)0.68
50.93 (0.59 to 1.46)0.74
60.95 (0.59 to 1.52)0.83
7+0.88 (0.56 to 1.38)0.57
Care home residence
Not living in care homeref1823
Living in care home0.64 (0.43 to 0.96)0.03

When adjusting for age and gender, vertebral fractures (OR 2.06 [95% CI (1.53 to 2.77)], p < 0.001) had stronger association with receiving a prescription whereas unspecified fracture (OR 1.57 [95% CI (1.17 to 2.10)], p < 0.001), and rib fractures (OR 0.34 [95% CI (0.19 to 0.60)], p < 0.001) both had a slightly attenuated relationship with receiving a prescription for bone protective medication versus hip fracture. When adjusting for age, multi‐morbidity (CMS) and gender, living in a care home (OR 0.58 [95% CI (0.38 to 0.88)], p = 0.01) had a stronger association of decreasing the odds of receiving a prescription than in the univariate model.

Multimorbidity still did not change the odds of receiving a prescription after adjusting for age (Table 3). The direction of these associations was not altered when restricting the analysis to those with an initial diagnosis of PD or those with 48 weeks of data before and after the index fracture, although it did weaken the association between prescriptions and care home residency (Table A6 and A7).

TABLE 3

Minimally adjusted logistic regression models to look at factors predicting bone protective medication prescriptions

Odds ratio (95% CI)N p‐value
Fracture type (unadjusted)
Hipref1823
Vertebral1.84 (1.38 to 2.45)<0.001
Wrist0.68 (0.44 to 1.05)0.08
Humerus0.80 (0.57 to 1.12)0.19
Rib0.28 (0.16 to 0.49)<0.001
Pelvis1.14 (0.71 to 1.85)0.58
Unspecified1.76 (1.33 to 2.33)<0.001
Multiple Fractures1.30 (0.62 to 2.71)0.49
Fracture type adjusted for age
Hipref1823
Vertebral1.98 (1.48 to 2.65)<0.001
Wrist0.75 (0.49 to 1.17)0.21
Humerus0.82 (0.58 to 1.16)0.26
Rib0.31 (0.18 to 0.55)<0.001
Pelvis1.15 (0.71 to 1.86)0.57
Unspecified1.84 (1.39 to 2.44)<0.001
Multiple fractures1.29 (0.62 to 2.71)0.50
Fracture type adjusted for age and gender
Hipref1823
Vertebral2.06 (1.53 to 2.77)<0.001
Wrist0.60 (0.38 to 0.93)0.02
Humerus0.72 (0.50 to 1.02)0.06
Rib0.34 (0.19 to 0.60)<0.001
Pelvis0.99 (0.61 to 1.61)0.96
Unspecified1.57 (1.17 to 2.10)<0.001
Multiple fractures1.23 (0.58 to 2.61)0.59
Cambridge multimorbidity score (unadjusted)
0/1ref1823
20.82 (0.51 to 1.33)0.42
30.83 (0.53 to 1.31)0.43
40.91 (0.58 to 1.43)0.68
50.93 (0.59 to 1.46)0.74
60.95 (0.59 to 1.52)0.83
7+0.88 (0.56 to 1.38)0.57
Cambridge multimorbidity score adjusted for age
0/1ref1823
20.77 (0.47 to 1.25)0.29
30.76 (0.48 to 1.21)0.25
40.81 (0.51 to 1.28)0.37
50.81 (0.51 to 1.28)0.36
60.82 (0.51 to 1.32)0.41
7+0.77 (0.49 to 1.21)0.26
Care home residency (unadjusted)
Noref1823
Yes0.64 (0.43 to 0.96)0.03
Care home residency adjusted for age
Noref1823
Yes0.58 (0.39 to 0.88)0.01
Care home residency adjusted for age and gender
Noref1823
Yes0.58 (0.38 to 0.88)0.01
Care home residency adjusted for age, gender and CMS
Noref1823
Yes0.58 (0.38 to 0.88)0.01

Discussion

Despite a significantly increased risk of sustaining fragility fractures, bone‐health and osteoporosis management is often overlooked when caring for people with parkinsonism. To understand the extent to which osteoporosis is treated in line with national guidelines, we investigated whether either bone protective medications, vitamin D and/or calcium supplements were prescribed. This was based on primary care records before and after people experienced fragility fractures. We identified treatment gaps and investigated potential predictors of prescriptions being made within 48 weeks following a fracture.

We identified a fracture rate of 27.3 per 1000 person years which aligns with the current literature. 6 , 17 Consistent with our previous findings 18 and with the results of the Parkinson's UK National Audit, 9 we identified a substantial treatment gap. Only 38% of this real‐world population who sustained a fragility fracture were receiving treatment within the recommended 16 week period. Increasing the treatment window to 48 weeks post fracture only increased this proportion to 53%. More people were prescribed vitamin D and/or calcium supplementation within 16 (58%) and 48 weeks (73%).

Being female, aged >75 years and having sustained either a vertebral or unspecified fragility fracture increased the odds of receiving a prescription for bone protective medications. Conversely, people with parkinsonism who had sustained rib fracture(s), or were residing in a care home were less likely to be prescribed bone protective medication. The direction of these associations was maintained when restricting the analysis to those with: more complete data (Table A7); or an initial diagnosis of PD (Table A6).

Due to initial diagnostic uncertainty, it is possible that some PD diagnoses may subsequently have been revised to an atypical parkinsonism. 19

Whilst demonstrating this striking and stark treatment gap, we have considered additional factors which may have impacted this finding. Using CPRD data it is possible to see which patients were prescribed bone protective medication in primary care. There is insufficient data to reliably determine whether bone health was considered and then no treatment was initiated (appropriately), adherence to prescribed treatments, or whether patients had received intravenous zoledronate via secondary care. There are several reasons why osteoporosis treatment may have been deemed inappropriate despite a patient sustaining a fragility fracture, including: concerns over polypharmacy; upper gastrointestinal disorders; renal impairment; patient preferences; bisphosphonate treatment holidays; life‐expectancy; concerns over side‐effects; or fracture risk assessment concluding treatment wasn’t warranted. 20 , 21 These legitimate reasons why treatments are sometimes not initiated will contribute to an over‐estimation of the reported treatment gap.

We might hypothesize that individuals with greater co‐morbidity burden are less likely to receive a prescription, but this was not evident in our data.

It is unclear to what extent the inability to capture treatment with zoledronate affects the treatment gap during the study period (2010 to 2019). Data from the National Hip Fracture Database (NHFD) indicates that in 2020 only 9% of patients were started on zoledronate following a hip fracture, 22 , 23 and in 2021 NOGG guidance was updated to recommend zoledronate as a first‐line treatment. 21 , 24 Prior to 2021, the recommendation was to use zoledronate if first‐line treatments, alendronate and risedronate, were not tolerated or contraindicated. 25 , 26 However, given that people with PD commonly experience difficulty swallowing, 27 perhaps oral bisphosphonates were deemed inappropriate and zoledronate was considered a suitable alternative in some instances.

Therefore, the inability to capture zoledronate may contribute to an over‐estimation of the identified treatment gap, however this gap is unlikely to be fully explained by this.

We excluded missing data from the treatment gap analysis. However, it is also important to consider those who did not receive a prescription before the last collection date for the practice, the end of the study period or who transferred to a practice without CPRD follow‐up. It is possible that these patients were later provided osteoporosis treatment. Amongst patients who died within 48 weeks and did not receive bone protective medication or supplementation, this may indicate a clinical decision that treatment was unlikely to be beneficial due to limited life expectancy.

When exploring demographic factors as predictors for bone protective medication prescription, it was unsurprising that being female compared to male increased the odds of prescriptions (OR 2.06 [95% CI (1.69 to 2.51)], p<0.001), given the known gender disparities in the treatment of osteoporosis. Recent work has demonstrated that in vertebral fracture cohorts the odds ratio for treatment was 1.82 favoring women 28 and, at hospital discharge following a hip fracture, only 2.7% (n = 3/110) of men compared to 27% (n = 60/253) of women were on anti‐resorptive treatment in a single center study in the United States. 29

Fracture type also affected the odds of receiving a prescription for bone protective medications. Vertebral fractures (OR 2.06 [1.53 to 2.77], p < 0.001) and unspecified osteoporotic fractures (OR 1.57 [1.17 to 2.10], p < 0.001) when compared to hip fracture increased the odds, whereas rib fractures (OR 0.34 [0.19 to 0.60], p < 0.001) when compared to hip fractures decreased the odds of prescription. We hypothesize that this could be explained by the different inpatient treatment received, although this cannot be addressed using CPRD data.

In the UK, rib fractures, unlike hip fractures, are more variably managed in different inpatient locations besides geriatrics, including orthopedics and general surgery 30 where there may be less familiarity with the use of osteoporosis treatments potentially leading to a discrepancy in the recommendation for bone protective medications. The finding that those with vertebral versus hip fracture have increased odds of receiving a prescription reflects findings from the US that following a vertebral fracture there is the largest increase in osteoporosis diagnosis and treatment rates compared to other fracture types. 31

Care home residency also reduced the odds of prescription after adjustment for age, gender and number of comorbidities (OR 0.58 [0.38 to 0.88], p = 0.01). However, the evidence for this was weakened when restricting the analysis to those with an initial diagnosis of PD or to those with 48 weeks of data before and after the index fracture. This is most likely explained by the small number of patients who were resident in a care home in these sub‐groups (Table A6 and A7) therefore widening the confidence interval.

This result is consistent with findings from US care home residents with dementia and high fracture risk, where only 11.6% received fracture prevention medications. 32 The authors also highlighted a potential lack of awareness about the appropriateness of treatment, as 10% of those receiving hospice care and 11% of individuals who were not dependent for activities of daily living were receiving medication for fracture prevention reflecting over and under‐treatment respectively. 32 Whilst the appropriateness of treatment could not be assessed in our study, it is important to consider that treatment for osteoporosis should be considered on a case‐by‐case basis accounting for several patient factors regardless of whether the patient resides in a care home.

Strengths and Limitations

This study is strengthened by the ability to assess the management of osteoporosis in a large, representative cohort of people with Parkinsonism across the United Kingdom. By using CPRD data it is possible to include previously under‐represented groups such as those who are older, with more advanced parkinsonism, care home residents, as well as people across the spectrum of parkinsonian disorders. 33 This is of particular importance given that people with atypical parkinsonism have greater fracture risk, alongside an osteoporosis treatment gap, 34 , 35 and there is often diagnostic uncertainty. 19

It was beyond the scope of this paper to ascertain whether patients were adherent to prescribed treatment or whether health care professional follow‐up was provided to maximize adherence. 14 Adherence to osteoporosis treatment is a well‐documented issue; persistence to oral bisphosphonates amongst post‐menopausal women is reported to be only 28% at 12 months. 36 Therefore, despite prescriptions being made it is likely that many patients were still without treatment following a fragility fracture.

When determining if patients were on treatment prior to fracture, for oral bisphosphonates patients were considered “on‐treatment” if they received a prescription in the 3 months prior to their fracture. However, this could mis‐classify participants if they were on treatment holiday after previously being prescribed oral bisphosphonates. It was also likely that patients being given zoledronate are mis‐categorized as “untreated” as it is not administered in the primary care setting and is therefore not reliably recorded within the CPRD data.

Furthermore, patients could have been misclassified as “not taking supplementation” if they are using over‐the‐counter vitamin D and/or calcium. However over‐the‐counter formulations may be sub‐standard in comparison to licensed medical products. 37 All of which could contribute to the observed treatment gaps.

As previously discussed, it is also possible that treatment options were considered and deemed inappropriate or declined by patients; however, this information is not routinely coded in CPRD data. It is also not possible using CPRD data to determine the circumstances surrounding the fracture. Whilst we included fracture sites typically associated with fragility fractures, it is possible that some of these fractures occurred from a trauma greater than a fall from standing height and are also contributing to an over‐estimation of the treatment gap as they are not indicative of osteoporosis.

Additionally, this population includes all people with parkinsonism who experienced a fracture between 2010 and 2019; in this study we consider the treatment decisions made after only the initial fracture which occurred within this period. However, it is possible that patients had multiple fracture events within this period or had fractures prior to 1st January 2010. Furthermore, the data available to us for analysis pre‐dates the updated NOGG guidance which mentions Parkinson's as an osteoporosis risk factor, 21 and our guidance on managing bone‐health in parkinsonism. 18 , 38 However, the treatment gap identified remains consistent with our 2025 findings that less than one third of people with parkinsonism are treated in‐line with the NOGG guidelines. 18

There remains a significant osteoporosis treatment gap within the parkinsonian population. Men with parkinsonism, those living in a care home, and those who sustain rib fractures are at increased odds of not receiving a prescription for bone protective medication following a fracture. Addressing this gap might reasonably be expected to prevent future fragility fractures and the associated serious and negative sequalae in this vulnerable and at‐risk population.

Author Roles

(1) Research project: A. Conception, B. Organization, C. Execution, (2) Statistical analysis: A. Design, B. Execution, C. Review and critique; (3) Manuscript preparation: A. Writing of the first draft, B. Review and critique.

K.C.N.: 1A, 1B, 1C, 2A, 2B, 3A.

E.J.H.: 1A, 1B, 1C, 2A, 2C, 3B.

E.T.: 1A, 1B, 1C, 2A, 2C, 3B.

Disclosures

Ethical Compliance Statement: This study is based in part on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency (protocol number 20_000060). However, the interpretation and conclusions contained in this report are those of the author's alone. The authors confirm that the approval of an institutional review board and patient consent were not required for this work. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Funding Sources and Conflict of Interest: This study was funded by the Gatsby Foundation (GAT3676). EJH is HEFCE funded for her academic work. ET is funded by a National Institute for Health and Care Research Academic Clinical Lectureship. The authors declare that there are no conflicts of interest relevant to this work.

Financial Disclosures for the Previous 12 Months: EJH is HEFCE funded by University of Bristol for her academic work and has received research funding from the NIHR, the British Geriatrics Society, the Gatsby Foundation, the Alzheimer's Society, Royal Osteoporosis Society, the Dunhill Society, and Parkinson's UK. She has received travel support, honoraria, and/or sat on advisory boards for Kyowa Kirin, AbbVie, Luye, the CME institute, Ever, Simbec Orion, the Neurology Academy, and Bial. ET is funded by a National Institute for Health and Care Research Academic Clinical Lectureship.

KCN is funded by the University of Bristol.

Acknowledgments

The authors acknowledge Savannah Haworth's role in assessing Read codes for clinically relevant fragility fractures.

Data Availability Statement

This study is based in part on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency. However, the interpretation and conclusions contained in this report are those of the author's alone.

References

1 Schini M , Vilaca T , Poku E , et al. The risk of hip and non‐vertebral fractures in patients with Parkinson's disease and parkinsonism: a systematic review and meta‐analysis . Bone 2020 ;132 :115173. 10.1016/J.BONE.2019.115173 . 31790846
2 Allen NE , Schwarzel AK , Canning CG . Recurrent falls in Parkinson's disease: a systematic review . Parkinsons Dis 2013 ;2013 :1Not reported16 . 10.1155/2013/906274 . PMC3606768 23533953
3 Pouwels S , Bazelier MT , De Boer A , et al. Risk of fracture in patients with Parkinson's disease . Osteoporos Int 2013 ;24 (8 ):2283Not reported2290 . 10.1007/S00198-013-2300-2/TABLES/4 . 23430103
4 Newman JM , Sodhi N , Wilhelm AB , et al. Parkinson's disease increases the risk of perioperative complications after total knee arthroplasty: a nationwide database study . Knee Surg Sports Traumatol Arthrosc 2019 ;27 (7 ):2189Not reported2195 . 10.1007/S00167-018-4970-Y/TABLES/4 . 29785449
5 Nguyen PV , Hjelholt TJ , Heide‐Jørgensen U , Pedersen AB . Postoperative complications, mortality, and quality of in‐hospital care among hip fracture patients with Parkinson's disease . Injury 2022 ;53 (6 ):2150Not reported2157 . 10.1016/J.INJURY.2022.03.015 . 35296377
6 Walker RW , Chaplin A , Hancock RL , Rutherford R , Gray WK . Hip fractures in people with idiopathic Parkinson's disease: incidence and outcomes . Mov Disord 2013 ;28 (3 ):334Not reported340 . 10.1002/MDS.25297 . 23389925
7 Harris‐Hayes M , Willis AW , Klein SE , Czuppon S , Crowner B , Racette BA . Relative mortality in U.S. Medicare beneficiaries with Parkinson disease and hip and pelvic fractures . J Bone Joint Surg Am 2014 ;96 (4 ):e27. 10.2106/JBJS.L.01317 . PMC3918936 24553896
8 Parkinson's Excellence Network . Better Bone Health Service Improvement Project 1 Executive summary Background ; 2020 .
9 Parkinson's Excellence Network . 2022 UK Parkinson's Audit‐Summary Report ; 2022 .
10 Gregson CL , Dennison EM , Compston JE , et al. Disease‐specific perception of fracture risk and incident fracture rates: GLOW cohort study . Osteoporos Int 2014 ;25 (1 ):85Not reported95 . 10.1007/S00198-013-2438-Y . PMC3867337 23884437
11 Herrett E , Gallagher AM , Bhaskaran K , Forbes H , Mathur R , van Staa T , Smeeth L . Data resource profile: clinical practice research datalink (CPRD) . Int J Epidemiol 2015 ;44 (3 ):827Not reported836 . 10.1093/IJE/DYV098 . PMC4521131 26050254
12 CPRD . Data quality | CPRD ; Accessed July 15, 2025. https://www.cprd.com/data-quality.
13 Watson J , Nicholson BD , Hamilton W , Price S . Identifying clinical features in primary care electronic health record studies: methods for codelist development . BMJ Open 2017;7 (11 ):e019637. 10.1136/BMJOPEN-2017-019637 . PMC5719324 29170293
14 Royal Osteoporosis Society . Effective Secondary Prevention of Fragility Fractures: Clinical Standards for Fracture Liaison Services ; 2019 .
15 StataCorp . Stata Statistical Software: Release 18 .
16 Payne RA , Mendonca SC , Elliott MN , et al. Development and validation of the Cambridge multimorbidity score . CMAJ 2020 ;192 (5 ):E107Not reportedE114 . 10.1503/CMAJ.190757/-/DC1 . PMC7004217 32015079
17 Fleet JL , Carter B , Cadarette SM , et al. Fracture incidence and osteoporosis treatment in Parkinson's disease: a population‐based cohort study . Osteoporos Int 2026 ;37 :459Not reported467 . 10.1007/S00198-025-07802-9 . 41369770
18 Naylor KC , Tenison E , Hardcastle SA , et al. Assessing and managing bone health and fracture risk in Parkinson's disease: the BONE PARK 2 protocol . Age Ageing 2025 ; 54 (3 ):afaf052. 10.1093/AGEING/AFAF052 . PMC11920699 40104975
19 Adler CH , Beach TG , Hentz JG , et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study . Neurology 2014 ;83 (5 ):406Not reported412 . 10.1212/WNL.0000000000000641 . PMC4132570 24975862
20 NICE . Bisphosphonates Prescribing information ; Accessed January 3, 2025. https://cks.nice.org.uk/topics/osteoporosis-prevention-of-fragility-fractures/prescribing-information/bisphosphonates/.
21 NOGG . Clinical guideline for the prevention and treatment of osteoporosis .
22 Johansen A , Sahota O , Dockery F , et al. Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture . Age Ageing 2023 ;52 (9 ):1Not reported9 . 10.1093/AGEING/AFAD172 . PMC10542103 37776543
23 Royal College of Physicians . Facing New Challenges: The National Hip Fracture Database report on 2020 .
24 Gregson CL , Compston JE . New National Osteoporosis Guidance‐implications for geriatricians . Age Ageing 2022 ;51 (4 ):afac044. 10.1093/AGEING/AFAC044 . PMC9760060 35403198
25 Compston J , Bowring C , Cooper A , et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013 . Maturitas 2013 ;75 (4 ):392Not reported396 . 10.1016/j.maturitas.2013.05.013 . 23810490
26 Compston J , Cooper A , Cooper C , et al. UK clinical guideline for the prevention and treatment of osteoporosis . Arch Osteoporos 2017 ; 12 (1 ):43 . 10.1007/s11657-017-0324-5 . PMC5397452 28425085
27 Kalf JG , de Swart BJM , Bloem BR , Munneke M . Prevalence of oropharyngeal dysphagia in Parkinson's disease: a meta‐analysis . Parkinsonism Relat Disord 2012 ;18 (4 ):311Not reported315 . 10.1016/j.parkreldis.2011.11.006 . 22137459
28 Ali R , Al‐Sudani H , Hanoodi M , et al. OP0032 gender disparities in osteoporosis diagnosis and management among patients with vertebral fractures: insights from a large‐scale database study . Ann Rheum Dis 2024 ;83 (Suppl 1 ):143Not reported144 . 10.1136/ANNRHEUMDIS-2024-EULAR.1694 .
29 Kiebzak GM , Beinart GA , Perser K , Ambrose CG , Siff SJ , Heggeness MH . Undertreatment of osteoporosis in men with hip fracture . Arch Intern Med 2002 ;162 (19 ):2217Not reported2222 . 10.1001/ARCHINTE.162.19.2217 . 12390065
30 Birse F , Williams H , Shipway D , Carlton E . Blunt chest trauma in the elderly: an expert practice review . Emerg Med J 2020 ;37 (2 ):73Not reported78 . 10.1136/EMERMED-2019-209143 . 31831589
31 Weaver J , Sajjan S , Michael Lewiecki E , Harris ST . Diagnosis and treatment of osteoporosis before and after fracture: a side‐by‐side analysis of commercially insured and Medicare advantage osteoporosis patients . 2017 ;23 (7 ):735Not reported744 . 10.18553/JMCP.2017.23.7.735 . PMC10398230 28650253
32 Niznik JD , Li X , Gilliam MA , et al. Are nursing home residents with dementia appropriately treated for fracture prevention? J Am Med Dir Assoc 2020 ;22 (1 ):28 . 10.1016/J.JAMDA.2020.11.019 . PMC8358966 33321079
33 Buckley M , O'Neill D . Ageism in studies of rehabilitation in parkinson's disease . J Am Geriatr Soc 2015 ;63 (7 ):1470Not reported1471 . 10.1111/JGS.13550 . 26189851
34 Kobylecki C , Glasse H , Amin J , Gregson CL , Lyell V , Henderson EJ . Fracture risk assessment in atypical parkinsonian syndromes . Mov Disord Clin Pract 2021 ;8 (3 ):385Not reported389 . 10.1002/MDC3.13146 . PMC8015890 33816667
35 Yarnall AJ , Duncan GW , Khoo TK , Burn DJ . Falling short: underestimation of fracture risk in atypical parkinsonian syndromes . Parkinsonism Relat Disord 2012 ;18 (5 ):692Not reported693 . 10.1016/J.PARKRELDIS.2012.01.004 . 22265139
36 Morley J , Moayyeri A , Ali L , Taylor A , Feudjo‐Tepie M , Hamilton L , Bayly J . Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK clinical practice research datalink . Osteoporos Int 2019 ;31 (3 ):533Not reported545 . 10.1007/S00198-019-05228-8 . PMC7076063 31758206
37 Wan M , Patel A , Patel JP , Rait G , Jones SA , Shroff R . Quality and use of unlicensed vitamin D preparations in primary care in England: retrospective review of national prescription data and laboratory analysis . Br J Clin Pharmacol 2021 ;87 (3 ):1338Not reported1346 . 10.1111/BCP.14521 . 32803772
38 Henderson EJ , Lyell V , Bhimjiyani A , Amin J , Kobylecki C , Gregson CL . Management of fracture risk in Parkinson's: a revised algorithm and focused review of treatments . Parkinsonism Relat Disord 2019 ;64 :181Not reported187 . 10.1016/J.PARKRELDIS.2019.03.021 . 30992234
Appendix A
Figure A1

Directed acyclic graphs for the minimally adjusted logistic regressions. This directed acyclic graph was developed using the DAGitty software1 to visually represent the causal and non‐causal associations that informed the minimally adjusted logistic regression models. 11 Textor J, van der Zander B, Gilthorpe MS, Liskiewicz M, Ellison GT. Robust causal inference using directed acyclic graphs: the R package “dagitty.” Int J Epidemiol. 2016;45(6):1887 to 94.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure A2

Reasons for incomplete follow‐up: bone protective medications.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure A3

Reasons for incomplete follow‐up: vitamin D and/or calcium supplements.

Figure image at the original source: open the original paper. This file is not included in this text import.
TABLE A1

Included parkinsonism read codes

Description (as listed in CPRD medical.txt file)MedcodeRead code
Parkinson's disease4321F12.00
Parkinsonism with OH8956F130300
Dementia in Parkinson's disease9509Eu02300
Parkinson's disease NOS14,912F12z.00
Parkinsonism in diseases classified elsewhere86,062Fyu2200
Paralysis agitans1691F120.00
Vascular parkinsonsim100,128F124.00
Lewy body disease7572F116.00
[X]Lewy body dementia26,270Eu02500
Multiple system atrophy22,454F174.00
Shy‐Drager syndrome35,839F130500
Progressive supranuclear palsy9385F24y000
Progressive supranuclear ophthalmoplegia40,553F130400
Steele‐Richardson Oszewski syndrome93,910F24y012
Steele Richardson Oszewski syn49,034F24y011
Steele‐Richardson‐Oszewski syndrome7037F24y200
Supranucelar paralysis29,515F36y000
Corticobasal degeneration107,650F11y200
Cerebral degeneration in Parkinson's disease96,860F11x900
TABLE A2

Included fragility fracture read codes.

Description (as listed in CPRD medical.txt file)MedcodeRead code
Hip
Hip fracture1994S30.11
Fracture of neck of femur2225S30.00
Closed fracture of proximal femur, pertrochanteric5301S302.00
Prmy open red+int fxn prox femoral # + screw/nail+plate device57427K1D000
Closed reduction of fracture of hip66607K1L400
Closed fracture of femur, intertrochanteric8648S302400
Cls red+int fxn proximal femoral # + screw/nail device alone87197K1J000
DHS‐Dynamic hip screw primary fixation of neck of femur97927K1D01E
Hip fracture NOS10,570S30y.11
Dynamic hip screw primary fixation of neck of femur12,5447K1D01F
Cls # prox femur, subcapital, Garden grade unspec.17,019S300500
H/O: hip fracture17,93614G7.00
Closed fracture of neck of femur NOS18,273S30y.00
Cls # proximal femur, trochanteric section, unspecified19,117S302000
Open fracture proximal femur, subcapital, Garden grade III23,803S301800
Closed fracture of unspecified proximal femur24,276S30w.00
Prim open reduct # neck femur & op fix‐Richards screw24,4937K1D01A
Pertrochanteric fracture28,965S304.00
Closed fracture proximal femur, subtrochanteric29,145S302200
Prmy open red+int fxn prox femoral # + screw/nail device alone33,6247K1D600
Closed fracture proximal femur, subcapital, Garden grade II33,957S300700
Closed fracture proximal femur, subcapital, Garden grade IV34,078S300900
Closed fracture proximal femur, subcapital, Garden grade I34,351S300600
Prmy open red+int fxn prox fem # + screw/nail+intramed device34,7647K1D700
Primary int fxn(no red) prox fem # + screw/nail device alone35,0047K1J500
Closed fracture head of femur36,391S300400
Closed fracture proximal femur, subcapital, Garden grade III36,599S300800
Open fracture of neck of femur NOS38,054S30z.00
Closed fracture proximal femur, transcervical38,489S300.00
Primary int fxn(no red) prox fem # + screw/nail+plate device38,8567K1J700
Open fracture proximal femur, subcapital, Garden grade unspec38,878S301500
Open fracture of femur, intertrochanteric39,396S303400
Cls # prox femur, intracapsular section, unspecified39,984S300000
Cl red intracaps fract neck femur fix − Smith‐Petersen nail40,9997K1J012
Primary int fxn(no red) prox fem # + scrw/nail+intramed device44,5947K1J600
Cls # of proximal femur, pertrochanteric section, NOS44,735S302z00
Closed fracture proximal femur, intertrochanteric, two part45,141S302100
Prim open reduct # neck femur & op fix − Neufield nail plate46,2587K1D018
Primary cls red+int fxn prox fem # + screw/nail+plate device46,9597K1JD00
Closed fracture proximal femur, other transcervical49,209S300y00
Opn # proximal femur, intracapsular section, unspecified50,727S301000
Cls # proximal femur, intertrochanteric, comminuted51,216S302300
Closed fracture, base of neck of femur51,861S300311
Open fracture proximal femur, subcapital, Garden grade IV51,999S301900
Closed fracture proximal femur, basicervical52,194S300300
Prim op red # nck femur and op fix‐Charnley compression screw52,3957K1D012
Cl red intracaps frac neck femur fix‐Garden cannulated screw53,6707K1J011
Prim cls rd + int fxn prox fem # + screw/nail+intramdulry device54,8197K1JC00
Primary cls red+int fxn prox fem # + screw/nail device alone55,3867K1JB00
Prim open red # neck femur and op fix‐McLaughlin nail plate56,5687K1D017
Cls red+int fxn prox femoral # + Richard's cannulat hip screw57,5147K1J013
Prim open reduct # neck femur and op fix‐Ross Brown nail57,8847K1D01B
Prim op red # nck femur and op fix‐Zickel intramed nail plate57,8897K1D01D
Open fracture of unspecified proximal femur58,642S30x.00
Prim open reduct # neck femur and op fix‐Blount nail plate58,8177K1D011
Open fracture proximal femur, subcapital, Garden grade I60,885S301600
Open fracture of proximal femur, pertrochanteric61,733S303.00
Closed fracture proximal femur, transcervical, NOS62,966S300z00
Prim open reduct # neck femur and op fix‐Pugh nail plate65,5367K1D019
Closed fracture proximal femur, midcervical section65,690S300200
Open fracture proximal femur, subcapital, Garden grade II67,394S301700
Open # of proximal femur, trochanteric section, unspecified67,633S303000
Closed fracture of femur, subcapital68,229S300y11
Open fracture proximal femur, other transcervical68,668S301y00
Primary external fixation (without reduction) prox femoral #70,0187K1K300
Open fracture of proximal femur, pertrochanteric, NOS70,479S303z00
Open fracture proximal femur, subtrochanteric71,282S303200
Open fracture of femur, subcapital73,234S301y11
Open fracture proximal femur, transcervical73,981S301.00
Closed fracture‐subluxation, hip joint93,374S4E2.00
Prim open reduct # neck femur and op fix‐Holt nail94,7147K1D014
Prim op red # nck femur and op fix‐Deyerle multiple hip pin97,3377K1D013
Open fracture proximal femur, intertrochanteric, comminuted97,971S303300
Open fracture base of neck of femur100,771S301311
Open fracture proximal femur, intertrochanteric, two part101,567S303100
Primary cls reduction+external fixation proximal femoral #102,3137K1K500
Prim open reduct # neck femur and op fix‐Jewett nail plate105,3527K1D015
Prim op red frac neck fem op fix us prox fem nail antirotatn105,8037K1DE00
Remanip intracap fract neck fem and fix using nail or screw107,3587K1Y000
Prim open reduct # neck femur and op fix‐Massie nail plate107,9327K1D016
Open fracture proximal femur, transcervical, NOS112,712S301z00
Open fracture proximal femur, midcervical section112,836S301200
Open fracture proximal femur, basicervical113,426S301300
Closed reduction of intracapsular # NOF internal fixat DHS39,3227K1Jd00
Vertebral fractures
Collapse of vertebra NOS2793N331.12
Closed fracture lumbar vertebra3888S104.00
Collapse of vertebra due to osteoporosis NOS4013N331L00
Fracture of vertebra without spinal cord lesion4409S10.12
Fracture of thoracic vertebra5381S15.00
Collapse of lumbar vertebra due to osteoporosis5841N331J00
Closed fracture lumbar vertebra, wedge8266S104100
Collapse of thoracic vertebra9319N331F00
Fracture of lumbar vertebra10,990S10B000
Collapse of lumbar vertebra11,543N331G00
Other specified closed fracture thoracic vertebra11,770S102y00
Fracture of lumbar spine and pelvis12,406S10B.00
Osteoporosis + pathological fracture thoracic vertebrae12,673N331900
Closed fracture of unspecified cervical vertebra15,613S100000
Collapse of thoracic vertebra15,837N331011
Fatigue fracture of vertebra16,895N1y1.00
Collapse of cervical vertebra17,008N331E00
Osteoporosis + pathological fracture lumbar vertebrae17,377N331800
Collapse of thoracic vertebra due to osteoporosis19,048N331K00
H/O: vertebral fracture19,23514G8.00
Collapse of lumbar vertebra23,686N331111
Closed fracture of seventh cervical vertebra24,672S100700
Closed fracture thoracic vertebra27,404S102.00
Closed fracture of fifth cervical vertebra27,575S100500
Closed fracture of sixth cervical vertebra27,654S100600
Fracture of first cervical vertebra28,133S10A000
Closed fracture thoracic vertebra, wedge28,524S102100
C6 vertebra closed fracture without spinal cord lesion33,503S100611
C2 vertebra closed fracture without spinal cord lesion33,967S100211
Fracture of second cervical vertebra34,403S10A100
C5 vertebra closed fracture without spinal cord lesion34,873S100511
C7 vertebra closed fracture without spinal cord lesion38,053S100711
Collapsed vertebra NOS38,728N331D00
Closed fracture thoracic vertebra not otherwise specified41,138S102z00
Closed fracture of fourth cervical vertebra41,548S100400
C1 vertebra closed fracture: no spinal cord lesion42,561S100111
Osteoporotic vertebral collapse44,386N331.14
Collapse of cervical vertebra due to osteoporosis45,736N331H00
Osteoporosis + pathological fracture cervical vertebrae48,772N331A00
C3 vertebra closed fracture without spinal cord lesion52,699S100311
Closed fracture cervical vertebra, wedge53,337S100H00
Closed fracture of third cervical vertebra60,593S100300
Open fracture lumbar vertebra, wedge65,302S105100
C4 vertebra closed fracture without spinal cord lesion67,358S100411
[X]Collapsed vertebra in diseases classified elsewhere73,900Nyu6700
[X]Fracture of other specified cervical vertebra94,638Syu1500
Collapse of cervical vertebra110,999N331C11
Wrist/distal radius
Wrist fracture: closed203S234.11
Closed reduction of fracture of wrist59517K1LM00
Fracture at wrist and hand level8056S242.00
Wrist fracture: open10,022S235.11
Closed fracture‐subluxation of the wrist17,921S4C2.00
Fracture‐dislocation or subluxation of wrist18,614S4C.00
Closed fracture dislocation of wrist34,429S4C0.00
Open fracture dislocation wrist42,844S4C1.00
[X]Fracture of other and unspecified parts of wrist and hand53,068Syu6500
Open fracture‐subluxation of the wrist59,219S4C3.00
Closed fracture distal radius, extra‐articular, other type19,058S234D00
Closed fracture distal radius, intra‐articular, die‐punch44,844S234C00
Closed fracture distal radius, intra‐articular, other type28,293S234E00
Closed fracture of the distal radius, unspecified1742S234200
Open fracture distal radius, extra‐articular other type53,698S235D00
Open fracture distal radius, intra‐articular other type63,588S235E00
Open fracture distal radius, intra‐articular, die‐punch104,070S235C00
Humerus
Fracture of humerus517S22.00
Fracture of upper end of humerus2101S226.00
Closed reduction of fracture of humerus63797K1LF00
Open fracture of the proximal humerus9420S221.00
Fracture of humerus NOS10,382S22z.00
Closed fracture proximal humerus, greater tuberosity11,044S220300
Closed fracture of the proximal humerus11,222S220.00
Closed fracture proximal humerus, neck11,313S220100
Closed fracture of humerus NOS19,186S222000
Closed fracture of humerus, shaft27,886S222100
Closed fracture proximal humerus, head28,739S220400
Closed fracture proximal humerus, four part29,137S220700
Fracture of shaft of humerus30,659S227.00
Closed fracture of proximal humerus, anatomical neck33,489S220200
Closed fracture of humerus, shaft or unspecified part36,464S222.00
Closed fracture of proximal humerus not otherwise specified38,353S220z00
Closed fracture proximal humerus, three part40,330S220600
Closed fracture of proximal humerus, unspecified part44,721S220000
Open fracture of proximal humerus not otherwise specified45,275S221z00
Open fracture proximal humerus, greater tuberosity48,239S221300
Closed fracture of humerus, upper epiphysis52,406S220500
Open fracture proximal humerus, neck53,622S221100
Open fracture of proximal humerus, unspecified part53,688S221000
Closed fracture of humerus, shaft or unspecified part NOS61,378S222z00
Open fracture proximal humerus, head70,486S221400
Open fracture proximal humerus, three part70,604S221600
Open fracture proximal humerus, four part70,653S221700
Open fracture of proximal humerus, anatomical neck71,207S221200
Rib
Closed fracture rib280S120.00
Closed fracture of rib, unspecified7831S120000
Fracture of rib9688S127.00
Multiple fractures of ribs10,696S127000
Closed fracture multiple ribs11,004S120900
Rib fracture NOS11,378S12z.11
Closed fracture of one rib16,494S120100
Multiple rib fractures17,107S29.12
Closed fracture of rib(s) NOS28,244S120z00
Cough fracture of ribs28,538S127100
Closed fracture of four ribs34,197S120400
Closed fracture of two ribs40,533S120200
Open fracture of two ribs44,826S121200
Open fracture rib48,224S121.00
Closed fracture of five ribs55,424S120500
Closed fracture of three ribs56,384S120300
Closed fracture of six ribs65,484S120600
Closed fracture of eight or more ribs68,652S120800
Open fracture multiple ribs71,452S121900
Open fracture of rib, unspecified73,613S121000
Open fracture of seven ribs73,956S121700
Closed fracture of seven ribs90,494S120700
Open fracture of rib(s) NOS101,560S121z00
Open fracture of one rib112,701S121100
Open fracture of four ribs113,739S121400
Pelvis
Fracture or disruption of pelvis738S13.00
Closed fracture pelvis, multiple pubic rami‐stable6667S132100
Closed fracture pelvis, single pubic ramus7004S132000
Other or multiple closed fracture of pelvis NOS11,639S134z00
Fracture of lumbar spine and pelvis12,406S10B.00
Closed fracture pelvis, coccyx14,834S108.00
Closed fracture of pelvis NOS28,375S13y.00
Other or multiple closed fracture of pelvis33,961S134.00
Closed fracture pelvis, ischium34,708S134100
Closed fracture‐dislocation of pelvis34,910S4J0100
Closed fracture pelvis, multiple pubic rami‐unstable46,592S132200
Unspecified site
Fragility fracture due to unspecified osteoporosis11,503N331M00
H/O: fragility fracture18,73114G6.00
[X]Unspecified osteoporosis with pathological fracture18,825NyuB800
Idiopathic osteoporosis with pathological fracture27,597N331600
Osteoporosis of disuse with pathological fracture33,526N331300
Postmenopausal osteoporosis with pathological fracture38,395N331B00
Postoophorectomy osteoporosis with pathological fracture39,334N331200
Drug‐induced osteoporosis with pathological fracture46,894N331500
[X]Other osteoporosis with pathological fracture57,301NyuB000
Postsurgical malabsorption osteoporosis with path fracture68,019N331400
Fragility fracture93,497N331N00
Minimal trauma fracture due to unspecified osteoporosis93,705N331M11
TABLE A3

Search Terms for prescriptions

Search termTarget
BisphosphonBisphosphonate/Bisphosphonic acid
DisphosphonDiphosphonate/Diphosphonic acid
AlendronAlendronate/Alendronic acid
MK‐217Alendronic acid (Alternative notation)
IbandronIbandronate/Ibandronic acid
RisedronRisedronate/Risedronic acid
ZolendronZoledronate/Zolendronic acid
EtidronEtidronate/Etidronic acid
EHDPEtidronate (alternative notation)
Strontium ranelateStrontium ranelate
Sodium clondronateSodium clondronate
TiludronTilundronate/Tilundronic acid
DenosumabDenosumab
AMG 162Denosumab (alternative notation)
RomosozumabRomosozumab
AMG 785Romosozumab (alternative notation)
TeriparatideTeriparatide
Human parathyroid hormoneHuman parathyroid hormone
AbaloparatideAbaloparatide
BNF chapters
060602Bone protective medications
090604Vitamin D supplementation
09050101Calcium supplementation
TABLE A4

Table of bone protective medication prescriptions over 48 weeks following a fragility fracture

TimelineCensored from study (N)Number of participants a Oral bisphosphonateStrontium ranelateDenosumabZoledronateAll
Before fracture 101823217620225
(Percentage)(11.9%)(0.3%)(0.1%)(0.0%)(12.3%)
Up to 16 weeks after23615875721753597
(Percentage)(36.0%)(1.1%)(0.3%)(0.2%)(37.6%)
Up to 32 weeks after36914546531893683
(Percentage)(44.9%)(1.2%)(0.6%)(0.2%)(47.0%)
Up to 48 weeks after479134467818123711
(Percentage)(50.4%)(1.3%)(0.9%)(0.2%)(52.9%)

Note: This table displays the cumulative frequency of each medication type and all bone protective medications, starting before the fracture event followed by 16 week intervals.

a

The number of people with available data within each time window for bone protective medication.

TABLE A5

Table of vitamin D and/or calcium supplement prescriptions over 48 weeks following a fragility fracture

TimelineCensored from study (N)Number of participants a Supplementation b
Before fracture 101823442
(Percentage)(24.2%)
Up to 16 weeks after1811642951
(Percentage)(57.9%)
Up to 32 weeks after26915541054
(Percentage)(67.8%)
Up to 48 weeks after33014931093
(Percentage)(73.2%)

Note: This table displays the cumulative frequency of supplementation (vitamin D and/or calcium) starting before the fracture event followed by 16 week intervals.

a

The number of people with available data within each time window for supplementation (Vitamin D and/or calcium).

b

Supplementation refers to a prescription being received for vitamin D and/or calcium.

TABLE A6

Sensitivity analysis restricted to those with an initial diagnosis of Parkinson's disease

Odds ratio (95% CI)N p‐value
Fracture type (unadjusted)
Hipref1521
Vertebral1.79 (1.31 to 2.43)< 0.001
Wrist0.64 (0.40 to 1.02)0.06
Humerus0.72 (0.50 to 1.04)0.08
Rib0.25 (0.13 to 0.46)< 0.001
Pelvis1.00 (0.57 to 1.73)0.99
Unspecified1.69 (1.24 to 2.30)< 0.001
Multiple fractures1.38 (0.61 to 3.12)0.44
Fracture type adjusted for age
Hipref1521
Vertebral1.91 (1.40 to 2.61)< 0.001
Wrist0.72 (0.45 to 1.16)0.18
Humerus0.74 (0.51 to 1.08)0.12
Rib0.28 (0.15 to 0.53)< 0.001
Pelvis1.00 (0.57 to 1.75)1.00
Unspecified1.79 (1.31 to 2.44)< 0.001
Multiple fractures1.40 (0.61 to 3.19)0.42
Fracture type adjusted for age and gender
Hipref1521
Vertebral2.04 (1.48 to 2.81)< 0.001
Wrist0.56 (0.34 to 0.91)0.02
Humerus0.64 (0.44 to 0.94)0.02
Rib0.31 (0.16 to 0.58)< 0.001
Pelvis0.85 (0.48 to 1.49)0.56
Unspecified1.53 (1.11 to 2.10)0.01
Multiple Fractures1.31 (0.56 to 3.02)0.53
Cambridge multimorbidity score unadjusted
0/1ref1521
20.80 (0.48 to 1.36)0.42
30.80 (0.48 to 1.33)0.39
40.88 (0.53 to 1.45)0.61
50.95 (0.58 to 1.57)0.85
60.97 (0.58 to 1.63)0.92
7+0.87 (0.53 to 1.43)0.58
Cambridge multimorbidity score adjusted for age
0/1ref1521
20.74 (0.44 to 1.27)0.28
30.74 (0.44 to 1.23)0.24
40.79 (0.48 to 1.31)0.36
50.84 (0.50 to 1.40)0.49
60.83 (0.49 to 1.41)0.50
7+0.76 (0.46 to 1.26)0.29
Care home residence (Unadjusted) a
Not living in care homeref1521
Living in care home0.75 (0.48 to 1.17)0.20
Care home residence adjusted for age
Not living in care homeref1521
Living in care home0.68 (0.44 to 1.07)0.10
Care home residence adjusted for age and gender
Not living in care homeref1521
Living in care home0.69 (0.44 to 1.08)0.11
Care home residence adjusted for age, gender and CMS
Not living in care homeref1521
Living in care home0.68 (0.43 to 1.08)0.10
a

There are now 94 (6.2%) of patients living in a care home.

TABLE A7

Sensitivity analysis restricted to those with 48‐weeks of data before and after the index fracture

Odds ratio (95% CI)N p‐value
Fracture type (Unadjusted)
Hipref765
Vertebral1.64 (1.05 to 2.56)0.03
Wrist0.58 (0.32 to 1.05)0.07
Humerus0.67 (0.39 to 1.13)0.13
Rib0.22 (0.10 to 0.48)<0.001
Pelvis0.56 (0.25 to 1.27)0.17
Unspecified1.57 (1.05 to 2.36)0.03
Multiple Fractures1.31 (0.37 to 4.63)0.67
Fracture type adjusted for age
Hipref765
Vertebral1.73 (1.10 to 2.71)0.02
Wrist0.62 (0.34 to 1.14)0.13
Humerus0.69 (0.40 to 1.17)0.17
Rib0.24 (0.11 to 0.52)<0.001
Pelvis0.57 (0.25 to 1.30)0.18
Unspecified1.61 (1.07 to 2.42)0.02
Multiple Fractures1.36 (0.38 to 4.84)0.64
Fracture type adjusted for age and gender
Hipref765
Vertebral1.78 (1.12 to 2.82)0.01
Wrist0.50 (0.27 to 0.94)0.03
Humerus0.60 (0.35 to 1.03)0.06
Rib0.26 (0.12 to 0.57)< 0.001
Pelvis0.48 (0.21 to 1.10)0.08
Unspecified1.44 (0.95 to 2.19)0.09
Multiple Fractures1.30 (0.36 to 4.69)0.69
Cambridge multimorbidity score unadjusted
0/1ref765
20.66 (0.29 to 1.48)0.31
30.85 (0.40 to 1.81)0.67
41.02 (0.48 to 2.16)0.96
50.85 (0.39 to 1.84)0.68
61.16 (0.53 to 2.56)0.71
7+1.08 (0.51 to 2.29)0.84
Cambridge multimorbidity score adjusted for age
0/1ref765
20.60 (0.26 to 1.37)0.23
30.79 (0.36 to 1.70)0.54
40.90 (0.42 to 1.93)0.78
50.76 (0.34 to 1.66)0.48
60.97 (0.43 to 2.17)0.93
7+0.91 (0.42 to 1.95)0.80
Care home residence (unadjusted) a
Not living in care homeref765
Living in care home0.54 (0.24 to 1.18)0.12
Care home residence adjusted for age
Not living in care homeref765
Living in care home0.48 (0.22 to 1.07)0.07
Care home residence adjusted for age and gender
Not living in care homeref765
Living in care home0.47 (0.21 to 1.05)0.07
Care home residence adjusted for age, gender and CMS
Not living in care homeref765
Living in care home0.44 (0.20 to 1.00)0.05
a

There are now 31 (4.1%) of patients living in a care home.

Publication and source details

Original title: Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism

Katie C. Naylor; Emily J. Henderson; Emma Tenison

Movement Disorders Clinical Practice · 2026

* Correspondence to: Katie C. Naylor, University of Bristol, Canynge Hall, Bristol, BS8 2PS, UK; E‐mail: katie.naylor@bristol.ac.uk
© 2026 The Author(s). Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Gatsby Charitable Foundation10.13039/501100000324 GAT3676

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T23:13:09.049507+00:00

DOI: 10.1002/mdc3.70652 · PMC13339595